Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2020 | Oct. 21, 2020 | |
Entity Information [Line Items] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2020 | |
Document Transition Report | false | |
Entity File Number | 0-15386 | |
Entity Registrant Name | CERNER CORPORATION | |
Entity Incorporation, State or Country Code | DE | |
Entity Address, Address Line One | 2800 Rockcreek Parkway | |
Entity Address, City or Town | North Kansas City, | |
Entity Address, State or Province | MO | |
Entity Tax Identification Number | 43-1196944 | |
Entity Address, Postal Zip Code | 64117 | |
City Area Code | 816 | |
Local Phone Number | 221-1024 | |
Title of 12(b) Security | Common Stock, $0.01 par value per share | |
Trading Symbol | CERN | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 306,589,898 | |
Entity Central Index Key | 0000804753 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q3 | |
Current Fiscal Year End Date | --12-31 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 28, 2019 |
Current assets: | ||
Cash and cash equivalents | $ 419,154 | $ 441,843 |
Short-term investments | 473,323 | 99,931 |
Receivables, net | 1,219,227 | 1,139,595 |
Inventory | 15,768 | 23,182 |
Prepaid expenses and other | 397,487 | 392,073 |
Total current assets | 2,524,959 | 2,096,624 |
Property and equipment, net | 1,867,600 | 1,858,772 |
Right-of-use assets | 109,659 | 123,155 |
Software development costs, net | 991,649 | 939,859 |
Goodwill | 907,105 | 883,158 |
Intangible assets, net | 330,837 | 364,439 |
Long-term investments | 423,315 | 419,419 |
Other assets | 205,688 | 209,196 |
Total assets | 7,360,812 | 6,894,622 |
Current liabilities: | ||
Accounts payable | 256,449 | 273,440 |
Deferred revenue | 320,294 | 360,025 |
Accrued payroll and tax withholdings | 328,663 | 245,843 |
Other current liabilities | 196,170 | 148,140 |
Total current liabilities | 1,101,576 | 1,027,448 |
Long-term Debt | 1,336,018 | 1,038,382 |
Deferred income taxes | 391,790 | 377,657 |
Other liabilities | 125,141 | 133,807 |
Total liabilities | 2,954,525 | 2,577,294 |
Shareholders' Equity: | ||
Common stock, $0.01 par value, 500,000,000 shares authorized, 372,272,953 shares issued at September 30, 2020 and 367,634,796 shares issued at December 28, 2019 | 3,723 | 3,676 |
Additional paid-in capital | 2,196,127 | 1,905,171 |
Retained earnings | 6,402,220 | 5,934,909 |
Treasury stock, 65,919,144 shares at September 30, 2020 and 56,723,546 shares at December 28, 2019 | (4,057,768) | (3,407,768) |
Accumulated other comprehensive loss, net | (138,015) | (118,660) |
Total shareholders' equity | 4,406,287 | 4,317,328 |
Total liabilities and shareholders' equity | $ 7,360,812 | $ 6,894,622 |
Common stock, par value | $ 0.01 | |
Common Stock, Shares Authorized | 500,000,000 | |
Common stock, shares issued | 372,272,953 | 367,634,796 |
Treasury Stock, Shares | 65,919,144 | 56,723,546 |
Consolidated Statements Of Oper
Consolidated Statements Of Operations - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 28, 2019 | Sep. 30, 2020 | Sep. 28, 2019 | |
Revenues | $ 1,368,673 | $ 1,429,428 | $ 4,110,763 | $ 4,250,366 |
Costs and expenses: | ||||
Costs of revenue | 231,889 | 271,778 | 698,268 | 793,655 |
Sales and client service | 625,402 | 707,743 | 1,907,138 | 2,026,825 |
Software development (Includes amortization of $61,578 and $183,786 for the three and nine months ended September 30, 2020, respectively; and $56,786 and $169,036 for the three and nine months ended September 28, 2019, respectively) | 186,826 | 187,526 | 551,101 | 548,934 |
General and administrative | 116,816 | 152,321 | 391,000 | 398,305 |
Amortization of acquisition-related intangibles | 12,789 | 21,283 | 43,031 | 64,809 |
Total costs and expenses | 1,173,722 | 1,340,651 | 3,590,538 | 3,832,528 |
Gain on sale of businesses | 216,869 | 0 | 216,869 | 0 |
Operating earnings | 411,820 | 88,777 | 737,094 | 417,838 |
Other income, net | 48,020 | 13,535 | 78,247 | 44,973 |
Earnings before income taxes | 459,840 | 102,312 | 815,341 | 462,811 |
Income taxes | (103,164) | (20,377) | (176,758) | (87,688) |
Net earnings | $ 356,676 | $ 81,935 | $ 638,583 | $ 375,123 |
Basic earnings per share | $ 1.17 | $ 0.26 | $ 2.08 | $ 1.17 |
Diluted earnings per share | $ 1.16 | $ 0.26 | $ 2.07 | $ 1.16 |
Basic weighted average shares outstanding | 305,759 | 315,876 | 306,759 | 320,282 |
Diluted weighted average shares outstanding | 308,366 | 319,113 | 309,124 | 323,361 |
Software development, amortization | $ 61,578 | $ 56,786 | $ 183,786 | $ 169,036 |
Consolidated Statements Of Comp
Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 28, 2019 | Sep. 30, 2020 | Sep. 28, 2019 | |
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] | ||||
Net earnings | $ 356,676 | $ 81,935 | $ 638,583 | $ 375,123 |
Foreign currency translation adjustment and other (net of taxes (benefit) of $351 and $688 for the three and nine months ended September 30, 2020; and $(409) and $(413) for the three and nine months ended September 28, 2019, respectively) | 9,611 | (11,679) | (1,738) | (9,458) |
Unrealized gain (loss) on cash flow hedge (net of taxes (benefit) of $745 and $(5,937) for the three and nine months ended September 30, 2020; and $(1,327) and $(5,396) for the three and nine months ended September 28, 2019, respectively) | 2,265 | (4,037) | (18,050) | (16,407) |
Unrealized holding gain (loss) on available-for-sale investments (net of taxes (benefit) of $(73) and $142 for the three and nine months ended September 30, 2020; and $5 and $286 for the three and nine months ended September 28, 2019, respectively) | (220) | 14 | 433 | 867 |
Comprehensive income | 368,332 | 66,233 | 619,228 | 350,125 |
Foreign currency translation adjustment and other, taxes (benefit) | 351 | (409) | 688 | (413) |
Unrealized loss on cash flow hedge, (taxes) benefit | (745) | 1,327 | 5,937 | 5,396 |
Change in net unrealized holding gain (loss) on available-for-sale investments, taxes (benefit) | $ (73) | $ 5 | $ 142 | $ 286 |
Consolidated Statements Of Cash
Consolidated Statements Of Cash Flows - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2020 | Sep. 28, 2019 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net earnings | $ 638,583 | $ 375,123 |
Adjustments to reconcile net earnings to net cash provided by operating activities: | ||
Depreciation and amortization | 518,987 | 509,559 |
Share-based compensation expense | 110,500 | 73,421 |
Provision for deferred income taxes | 21,554 | 22,793 |
Gain on sale of businesses | (216,869) | 0 |
Investment gains | (75,834) | (24,231) |
Changes in assets and liabilities: | ||
Receivables, net | (78,695) | 24,558 |
Inventory | 8,206 | 1,877 |
Prepaid expenses and other | (36,664) | (75,191) |
Accounts payable | (60,808) | (3,346) |
Accrued income taxes | 33,005 | (795) |
Deferred revenue | (32,071) | (89,400) |
Other accrued liabilities | 94,151 | 61,156 |
Net cash provided by operating activities | 924,045 | 875,524 |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Capital purchases | (238,053) | (388,588) |
Capitalized software development costs | (224,710) | (211,284) |
Purchases of investments | (511,378) | (317,979) |
Sales and maturities of investments | 213,309 | 507,258 |
Purchase of other intangibles | (29,698) | (25,794) |
Sale of businesses | 229,471 | 0 |
Acquisition of businesses, net of cash acquired | (35,766) | 0 |
Net cash used in investing activities | (596,825) | (436,387) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Long-term debt issuance | 300,000 | 600,000 |
Repayments of Long-term Debt | (2,500) | 0 |
Proceeds from exercise of stock options | 202,680 | 188,474 |
Payments to taxing authorities in connection with shares directly withheld from associates | (22,623) | (14,994) |
Treasury stock purchases | (650,000) | (1,020,542) |
Dividends paid | (166,277) | (57,293) |
Other financing activities | (6,807) | (8,450) |
Net cash provided by (used in) financing activities | (345,527) | (312,805) |
Effect of exchange rate changes on cash and cash equivalents | (4,382) | (4,028) |
Net increase (decrease) in cash and cash equivalents | (22,689) | 122,304 |
Cash and cash equivalents at beginning of period | 441,843 | 374,126 |
Cash and cash equivalents at end of period | $ 419,154 | $ 496,430 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Shareholders' Equity Statement - USD ($) $ in Thousands | Total | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Retained Earnings [Member]Cumulative Effect, Period of Adoption, Adjustment | Treasury Stock [Member] | AOCI Attributable to Parent [Member] |
Balance at Dec. 29, 2018 | $ 3,622 | $ 1,559,562 | $ 5,576,525 | $ (2,107,768) | $ (103,552) | ||
Common stock, shares issued at Dec. 29, 2018 | 362,213,000 | ||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Exercise of stock options | $ 7 | 11,716 | |||||
Exercise of stock options, shares | 706,000 | ||||||
Employee share-based compensation expense | 19,860 | ||||||
Other Comprehensive Income (Loss) | 2,958 | ||||||
Net earnings | 166,219 | ||||||
Balance at Mar. 30, 2019 | $ 3,629 | 1,591,138 | 5,742,744 | (2,107,768) | (100,594) | ||
Common Stock, shares issued at Mar. 30, 2019 | 362,919,000 | ||||||
Balance at Dec. 29, 2018 | $ 3,622 | 1,559,562 | 5,576,525 | (2,107,768) | (103,552) | ||
Common stock, shares issued at Dec. 29, 2018 | 362,213,000 | ||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net earnings | $ 375,123 | ||||||
Balance at Sep. 28, 2019 | $ 3,662 | 1,806,939 | 5,836,984 | (3,107,768) | (128,550) | ||
Common Stock, shares issued at Sep. 28, 2019 | 366,201,000 | ||||||
Balance at Mar. 30, 2019 | $ 3,629 | 1,591,138 | 5,742,744 | (2,107,768) | (100,594) | ||
Common stock, shares issued at Mar. 30, 2019 | 362,919,000 | ||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Exercise of stock options | $ 18 | 108,045 | |||||
Exercise of stock options, shares | 1,777,000 | ||||||
Employee share-based compensation expense | 23,024 | ||||||
Other Comprehensive Income (Loss) | (12,254) | ||||||
Treasury stock purchases | (600,000) | ||||||
Cash dividends declared ($0.18 per share) | (57,682) | ||||||
Net earnings | 126,969 | ||||||
Balance at Jun. 29, 2019 | $ 3,647 | 1,722,207 | 5,812,031 | (2,707,768) | (112,848) | ||
Common Stock, shares issued at Jun. 29, 2019 | 364,696,000 | ||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Exercise of stock options | $ 15 | 54,195 | |||||
Exercise of stock options, shares | 1,505,000 | ||||||
Employee share-based compensation expense | 30,537 | ||||||
Other Comprehensive Income (Loss) | (15,702) | ||||||
Treasury stock purchases | (400,000) | ||||||
Cash dividends declared ($0.18 per share) | (56,982) | ||||||
Net earnings | 81,935 | 81,935 | |||||
Balance at Sep. 28, 2019 | $ 3,662 | 1,806,939 | 5,836,984 | (3,107,768) | (128,550) | ||
Common Stock, shares issued at Sep. 28, 2019 | 366,201,000 | ||||||
Balance at Dec. 28, 2019 | $ 4,317,328 | $ 3,676 | 1,905,171 | 5,934,909 | $ (4,606) | (3,407,768) | (118,660) |
Common stock, shares issued at Dec. 28, 2019 | 367,634,796 | 367,635,000 | |||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Exercise of stock options | $ 26 | 114,050 | |||||
Exercise of stock options, shares | 2,543,000 | ||||||
Employee share-based compensation expense | 35,031 | ||||||
Other Comprehensive Income (Loss) | (40,703) | ||||||
Treasury stock purchases | (650,000) | ||||||
Cash dividends declared ($0.18 per share) | (55,206) | ||||||
Net earnings | 147,159 | ||||||
Balance at Mar. 31, 2020 | $ 3,702 | 2,054,252 | 6,022,256 | (4,057,768) | (159,363) | ||
Common Stock, shares issued at Mar. 31, 2020 | 370,178,000 | ||||||
Balance at Dec. 28, 2019 | $ 4,317,328 | $ 3,676 | 1,905,171 | 5,934,909 | $ (4,606) | (3,407,768) | (118,660) |
Common stock, shares issued at Dec. 28, 2019 | 367,634,796 | 367,635,000 | |||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Treasury stock purchases | $ 650,000 | ||||||
Net earnings | 638,583 | ||||||
Balance at Sep. 30, 2020 | $ 4,406,287 | $ 3,723 | 2,196,127 | 6,402,220 | (4,057,768) | (138,015) | |
Common Stock, shares issued at Sep. 30, 2020 | 372,272,953 | 372,273,000 | |||||
Balance at Mar. 31, 2020 | $ 3,702 | 2,054,252 | 6,022,256 | (4,057,768) | (159,363) | ||
Common stock, shares issued at Mar. 31, 2020 | 370,178,000 | ||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Exercise of stock options | $ 10 | 28,540 | |||||
Exercise of stock options, shares | 1,009,000 | ||||||
Employee share-based compensation expense | 37,549 | ||||||
Other Comprehensive Income (Loss) | 9,692 | ||||||
Cash dividends declared ($0.18 per share) | (55,602) | ||||||
Net earnings | 134,748 | ||||||
Balance at Jun. 30, 2020 | $ 3,712 | 2,120,341 | 6,101,402 | (4,057,768) | (149,671) | ||
Common Stock, shares issued at Jun. 30, 2020 | 371,187,000 | ||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Exercise of stock options | $ 11 | 37,866 | |||||
Exercise of stock options, shares | 1,086,000 | ||||||
Employee share-based compensation expense | 37,920 | ||||||
Other Comprehensive Income (Loss) | 11,656 | ||||||
Cash dividends declared ($0.18 per share) | (55,858) | ||||||
Net earnings | $ 356,676 | 356,676 | |||||
Balance at Sep. 30, 2020 | $ 4,406,287 | $ 3,723 | $ 2,196,127 | $ 6,402,220 | $ (4,057,768) | $ (138,015) | |
Common Stock, shares issued at Sep. 30, 2020 | 372,272,953 | 372,273,000 |
Supplemental Cash Flow Informat
Supplemental Cash Flow Information | 9 Months Ended |
Sep. 30, 2020 | |
Supplemental Cash Flow Elements [Abstract] | |
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] | Supplemental Disclosures of Cash Flow Information Nine Months Ended (In thousands) 2020 2019 Cash paid during the period for: Interest (including amounts capitalized of $12,040 and $12,575, respectively) $ 31,661 $ 20,756 Income taxes, net of refunds 78,519 65,171 Non-cash items: Lease liabilities recorded upon the commencement of operating leases 24,499 23,129 Capital purchases 17,395 7,600 |
Supplemental Cash Flow Inform_2
Supplemental Cash Flow Information details - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2020 | Sep. 28, 2019 | |
Supplemental Cash Flow Elements [Abstract] | ||
Interest Paid, Capitalized | $ 12,040 | $ 12,575 |
Interest Paid | 31,661 | 20,756 |
Income Taxes Paid, Net | 78,519 | 65,171 |
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | 24,499 | 23,129 |
Capital Expenditures Incurred but Not yet Paid | $ 17,395 | $ 7,600 |
Interim Statement Presentation
Interim Statement Presentation (Notes) | 9 Months Ended |
Sep. 30, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Interim Statement Presentation | Interim Statement Presentation Basis of Presentation The condensed consolidated financial statements included herein have been prepared by Cerner Corporation ("Cerner," the "Company," "we," "us" or "our") without audit, pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our latest annual report on Form 10-K. In management's opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the financial position and the results of operations and cash flows for the periods presented. Our interim results as presented in this Form 10-Q are not necessarily indicative of the operating results for the entire year. The condensed consolidated financial statements were prepared using GAAP. These principles require us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results could differ from those estimates. Fiscal Period End Prior to fiscal year 2020, our third fiscal quarter ended on the Saturday closest to September 30. The third quarter and year-to-date periods for 2019 presented herein consisted of 91 days and 273 days, respectively, and ended on September 28, 2019. In December 2019, our Board of Directors approved the change of our fiscal year to a calendar year, commencing with fiscal year 2020. Accordingly, the third quarter and year-to-date periods for 2020 presented herein consisted of 92 days and 277 days, respectively, and ended on September 30, 2020. All references to periods in these notes to condensed consolidated financial statements represent the respective periods described above ending on September 30, 2020 and September 28, 2019, unless otherwise noted. Supplemental Disclosures of Cash Flow Information Nine Months Ended (In thousands) 2020 2019 Cash paid during the period for: Interest (including amounts capitalized of $12,040 and $12,575, respectively) $ 31,661 $ 20,756 Income taxes, net of refunds 78,519 65,171 Non-cash items: Lease liabilities recorded upon the commencement of operating leases 24,499 23,129 Capital purchases 17,395 7,600 CARES Act Cash flows from operating activities for the first nine months of 2020 include the impact of $56 million of certain federal payroll taxes related to pay cycles in the second and third quarters of 2020, for which we have deferred remittance to the taxing authority as permitted under the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act"). We expect to continue to defer the remittance of such payroll taxes for the remainder of 2020, as permitted by the CARES Act, for which the remittances to the taxing authority are to be paid in equal amounts at the end of 2021 and 2022, respectively. At September 30, 2020, these deferred remittances are included in "Accrued payroll and tax withholdings" in our condensed consolidated balance sheets. Accounting Pronouncements Adopted in 2020 Credit Losses on Financial Instruments. In the first quarter of 2020, we adopted new guidance regarding impairment assessment for certain financial assets. Refer to Notes (3) and (4) for further details. Collaborative Arrangements. In November 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 , which clarifies when transactions between participants in a collaborative arrangement are within the scope of the FASB's recent revenue standard (Topic 606). Such guidance clarifies revenue recognition and financial statement presentation for transactions between collaboration participants. We adopted ASU 2018-18 in the first quarter of 2020. Such guidance did not have an impact on our consolidated financial statements and related disclosures. Recently Issued Accounting Pronouncements Reference Rate Reform. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform, such as the upcoming discontinuance of the London Interbank Offered Rate ("LIBOR"). The accommodations within ASU 2020-04 may be applied prospectively from the beginning of our 2020 first quarter through December 31, 2022. We are currently evaluating the effect that ASU 2020-04 may have on our contracts that reference LIBOR, specifically, our Third Amended and Restated Credit Agreement (as amended, the "Credit Agreement") and related interest rate swap. As of the date of this filing, we have not elected to apply any of the provisions of this standard. |
Revenue from Contracts with Cus
Revenue from Contracts with Customers (Notes) | 9 Months Ended |
Sep. 30, 2020 | |
Revenue from Contract with Customer [Abstract] | |
Revenue from Contract with Customer [Text Block] | Revenue Recognition Disaggregation of Revenue The following tables present revenues disaggregated by our business models: Three Months Ended 2020 2019 (In thousands) Domestic International Total Domestic International Total Licensed software $ 159,327 $ 12,367 $ 171,694 $ 144,599 $ 9,934 $ 154,533 Technology resale 45,217 1,896 47,113 65,103 5,072 70,175 Subscriptions 87,878 5,529 93,407 85,230 6,674 91,904 Professional services 433,127 46,768 479,895 446,562 60,893 507,455 Managed services 280,827 31,017 311,844 272,933 29,502 302,435 Support and maintenance 219,682 40,296 259,978 227,131 50,163 277,294 Reimbursed travel 4,711 31 4,742 23,705 1,927 25,632 Total revenues $ 1,230,769 $ 137,904 $ 1,368,673 $ 1,265,263 $ 164,165 $ 1,429,428 Nine Months Ended 2020 2019 (In thousands) Domestic Segment International Segment Total Domestic Segment International Segment Total Licensed software $ 444,774 $ 37,114 $ 481,888 $ 466,105 $ 40,018 $ 506,123 Technology resale 126,042 14,675 140,717 169,112 17,338 186,450 Subscriptions 260,095 19,749 279,844 246,505 19,460 265,965 Professional services 1,295,759 156,564 1,452,323 1,313,701 169,500 1,483,201 Managed services 836,242 92,114 928,356 818,818 85,661 904,479 Support and maintenance 663,399 144,296 807,695 679,214 151,454 830,668 Reimbursed travel 19,086 854 19,940 68,750 4,730 73,480 Total revenues $ 3,645,397 $ 465,366 $ 4,110,763 $ 3,762,205 $ 488,161 $ 4,250,366 The following tables present our revenues disaggregated by timing of revenue recognition: Three Months Ended 2020 2019 (In thousands) Domestic International Total Domestic International Total Revenue recognized over time $ 1,143,515 $ 132,891 $ 1,276,406 $ 1,143,470 $ 155,017 $ 1,298,487 Revenue recognized at a point in time 87,254 5,013 92,267 121,793 9,148 130,941 Total revenues $ 1,230,769 $ 137,904 $ 1,368,673 $ 1,265,263 $ 164,165 $ 1,429,428 Nine Months Ended 2020 2019 (In thousands) Domestic Segment International Segment Total Domestic Segment International Segment Total Revenue recognized over time $ 3,410,827 $ 437,791 $ 3,848,618 $ 3,403,965 $ 445,320 $ 3,849,285 Revenue recognized at a point in time 234,570 27,575 262,145 358,240 42,841 401,081 Total revenues $ 3,645,397 $ 465,366 $ 4,110,763 $ 3,762,205 $ 488,161 $ 4,250,366 Transaction Price Allocated to Remaining Performance Obligations As of September 30, 2020, the aggregate amount of transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts approximates $13.01 billion of which we expect to recognize approximately 30% of the revenue over the next 12 months and the remainder thereafter. Contract Liabilities Customer payments received in advance of satisfaction of the related performance obligations are deferred as contract liabilities. Such amounts are classified in our condensed consolidated balance sheets as "Deferred revenue". During the nine months ended September 30, 2020, we recognized $306 million of revenues that were included in our contract liability balance at the beginning of such period. Significant Customers A certain customer within our Domestic segment comprised 19% and 12% of our consolidated revenues for the third quarters of 2020 and 2019, respectively; and 17% and 11% for the first nine months of 2020 and 2019, respectively. Amounts due from this same customer comprised 14% of client receivables as of September 30, 2020. |
Receivables
Receivables | 9 Months Ended |
Sep. 30, 2020 | |
Receivables [Abstract] | |
Receivables | Receivables A summary of net receivables is as follows: (In thousands) September 30, 2020 December 28, 2019 Client receivables $ 1,370,394 $ 1,245,670 Less: Provision for expected credit losses 151,167 106,075 Total receivables, net $ 1,219,227 $ 1,139,595 A reconciliation of the beginning and ending amount of our provision for expected credit losses is as follows: (In thousands) Provision for expected credit losses - balance at December 28, 2019 $ 106,075 Cumulative effect of accounting change (ASU 2016-13) 4,606 Additions charged to costs and expenses 54,636 Deductions (14,150) Provision for expected credit losses - balance at September 30, 2020 $ 151,167 During the first nine months of 2020 and 2019, we received total client cash collections of $4.09 billion and $4.23 billion, respectively. Expected Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which provides a new impairment model for certain financial assets that is based on expected losses rather than incurred losses. Such guidance impacts how we determine our allowance for estimated uncollectible client receivables. The standard requires use of the modified retrospective (cumulative effect) transition approach as of the beginning of the first reporting period in which the guidance was effective, which for the Company was the first quarter of 2020. Under this transition method, the cumulative effect from prior periods upon applying this new guidance was recognized in our condensed consolidated balance sheets as of December 29, 2019. We did not recast comparative periods. A summary of such cumulative effect adjustment is as follows: (In thousands) Increase/(Decrease) Receivables, net $ (4,606) Retained earnings (4,606) The cumulative effect adjustment is the result of providing an allowance on unbilled client receivables, for which we have an unconditional right to invoice and receive payment in the future. Our estimates of expected credit losses for client receivables at both December 29, 2019 and September 30, 2020, were primarily based on historical credit loss experience and adjustments for certain asset-specific risk characteristics (i.e. known client financial hardship or bankruptcy). Exposure to credit losses may increase if our clients are adversely affected by changes in healthcare laws, reimbursement or payor models; economic pressures or uncertainty associated with local or global economic recessions; disruption associated with the COVID-19 pandemic; or other client-specific factors. Although we have historically not experienced significant credit losses, it is possible that there could be an adverse impact from potential adjustments to the carrying amount of client receivables as clients' cash flows are impacted by the COVID-19 pandemic and related economic uncertainty, which may be material. |
Investments
Investments | 9 Months Ended |
Sep. 30, 2020 | |
Investments [Abstract] | |
Investments | Investments Available-for-sale investments at September 30, 2020 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 56,855 $ — $ — $ 56,855 Time deposits 19,676 — — 19,676 Commercial Paper 1,600 — — 1,600 Government and corporate bonds 1,150 — — 1,150 Total cash equivalents 79,281 — — 79,281 Short-term investments: Time deposits 21,248 — — 21,248 Commercial paper 259,000 22 (7) 259,015 Government and corporate bonds 192,536 559 (35) 193,060 Total short-term investments 472,784 581 (42) 473,323 Long-term investments: Government and corporate bonds 91,605 180 (78) 91,707 Total available-for-sale investments $ 643,670 $ 761 $ (120) $ 644,311 Available-for-sale investments at December 28, 2019 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 185,666 $ — $ — $ 185,666 Time deposits 64,286 — — 64,286 Total cash equivalents 249,952 — — 249,952 Short-term investments: Time deposits 2,506 — — 2,506 Government and corporate bonds 83,272 52 (11) 83,313 Total short-term investments 85,778 52 (11) 85,819 Long-term investments: Government and corporate bonds 96,186 91 (67) 96,210 Total available-for-sale investments $ 431,916 $ 143 $ (78) $ 431,981 We sold available-for-sale investments for proceeds of $5 million and $181 million during the nine months ended September 30, 2020 and September 28, 2019, respectively, resulting in insignificant gains/losses in each period. Other Investments At September 30, 2020 and December 28, 2019, we had investments in equity securities that do not have readily determinable fair values of $320 million and $314 million, respectively, accounted for in accordance with Accounting Standards Codification Topic ("ASC") 321, Investments-Equity Securities . Such investments are included in "Long-term investments" in our condensed consolidated balance sheets. We did not record any changes in the measurement of such investments during the nine months ended September 30, 2020 and September 28, 2019, respectively. At June 30, 2020 and December 28, 2019, we had investments in equity securities with readily determinable fair values of $41 million and $14 million, respectively, accounted for in accordance with ASC 321. Such investments were included in "Short-term investments" in our condensed consolidated balance sheets. Changes in the measurement of such investments favorably impacted "Other income, net" by $49 million and $76 million for the three and nine months ended September 30, 2020, respectively, and $9 million for both the three and nine months ended September 28, 2019. In August 2020, we sold these investments for cash proceeds of $90 million. At September 30, 2020 and December 28, 2019, we had investments in equity securities reported under the equity method of accounting of $11 million and $9 million, respectively. Such investments are included in "Long-term investments" in our condensed consolidated balance sheets. Impairment Assessment We adopted ASU 2016-13 in the first quarter of 2020, which made certain amendments to the model used to assess available-for-sale debt securities for impairment. Such guidance provides that an available-for-sale debt security is impaired if the fair value of the security is less than its amortized cost basis. A determination is made whether the decline in fair value below the amortized cost basis has resulted from a credit loss or other factors, such as market liquidity or changes in interest rates. Impairment related to credit losses is recognized in net earnings, whereas impairment related to other factors is recognized as a component of accumulated other comprehensive loss, net. During the nine months ended September 30, 2020, we did not recognize any impairment on our available-for-sale debt securities through net earnings. |
Debt
Debt | 9 Months Ended |
Sep. 30, 2020 | |
Debt Disclosure [Abstract] | |
Debt Disclosure | Long-term Debt The following is a summary of indebtedness outstanding: (In thousands) September 30, 2020 December 28, 2019 Credit agreement loans due May 5, 2024 $ 600,000 $ 600,000 Senior notes: Series 2020-A due March 11, 2030 300,000 — Series 2015-A due February 15, 2022 225,000 225,000 Series 2015-B due February 14, 2025 200,000 200,000 Other 11,662 14,162 Total indebtedness 1,336,662 1,039,162 Less: debt issuance costs (644) (780) Long-term debt $ 1,336,018 $ 1,038,382 Credit Agreement As of September 30, 2020, the interest rate on revolving credit loans outstanding under our Credit Agreement was 0.95% based on LIBOR plus the applicable spread. We are exposed to market risk from fluctuations in the variable interest rates on outstanding indebtedness under our Credit Agreement. In order to manage this exposure, we have entered into an interest rate swap agreement to hedge the variability of cash flows associated with such interest obligations. The interest rate swap is designated as a cash flow hedge, which effectively fixes the interest rate on the hedged indebtedness under our Credit Agreement at 3.06%. At September 30, 2020 and December 28, 2019, this swap was in a net liability position with an aggregate fair value of $41 million and $17 million, respectively; which is presented in our condensed consolidated balance sheets in "Other current liabilities" . Series 2020-A Senior Notes In March 2020, we issued $300 million aggregate principal amount of 2.50% senior unsecured Series 2020-A notes (the "Series 2020-A Notes") due March 11, 2030, pursuant to a Master Note Agreement we entered into in November 2019, and subsequently amended on October 8, 2020 (collectively and as amended, the "2019 Shelf Agreement"). Interest on |
Fair Value Measurements
Fair Value Measurements | 9 Months Ended |
Sep. 30, 2020 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements We determine fair value measurements used in our consolidated financial statements based upon the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below: • Level 1 – Valuations based on quoted prices in active markets for identical assets or liabilities that the entity has the ability to access. • Level 2 – Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. • Level 3 – Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The following table details our investments in available-for-sale debt securities measured and recorded at fair value on a recurring basis at September 30, 2020: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 56,855 $ — $ — Time deposits Cash equivalents — 19,676 — Commercial paper Cash equivalents — 1,600 — Government and corporate bonds Cash equivalents — 1,150 — Time deposits Short-term investments — 21,248 — Commercial paper Short-term investments — 259,015 — Government and corporate bonds Short-term investments — 193,060 — Government and corporate bonds Long-term investments — 91,707 — The following table details our investments in available-for-sale debt securities measured and recorded at fair value on a recurring basis at December 28, 2019: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 185,666 $ — $ — Time deposits Cash equivalents — 64,286 — Time deposits Short-term investments — 2,506 — Government and corporate bonds Short-term investments — 83,313 — Government and corporate bonds Long-term investments — 96,210 — Our investments in equity securities with readily determinable fair values accounted for in accordance with ASC 321 were measured and recorded at fair value on a recurring basis using a Level 2 valuation. The fair value of such arrangements was based on quoted prices in active markets, reduced by a percentage reflecting a discount for lack of marketability. Our interest rate swap agreement is measured and recorded at fair value on a recurring basis using a Level 2 valuation. The fair value of such agreement is based on the market standard methodology of netting the discounted expected future variable cash receipts and the discounted future fixed cash payments. The variable cash receipts are based on an expectation of future interest rates derived from observed market interest rate forward curves. Since these inputs are observable in active markets over the terms that the instrument is held, the derivative is classified as Level 2 in the hierarchy. We estimate the fair value of our long-term, fixed rate debt using a Level 3 discounted cash flow analysis based on current borrowing rates for debt with similar maturities. We estimate the fair value of our long-term, variable rate debt using a Level 3 discounted cash flow analysis based on LIBOR rate forward curves. The fair value of our long-term debt at September 30, 2020 and December 28, 2019 was approximately $1.34 billion and $1.07 billion, respectively. The carrying amount of such debt at September 30, 2020 and December 28, 2019 was $1.33 billion and $1.03 billion, respectively. |
Gain on Sale of Businesses
Gain on Sale of Businesses | 9 Months Ended |
Sep. 30, 2020 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Gain on Sale of Businesses | Gain on Sale of Businesses Germany and Spain On July 1, 2020, we sold certain of our business operations, primarily conducted in Germany and Spain, to affiliates of CompuGroup Medical SE & Co. KGaA ("CGM"), as a part of our portfolio management strategy. Such operations included the associates, intellectual property, client contracts, other assets, and liabilities related to our medico ® , Selene ® , Soarian Health Archive ® , and Soarian ® Integrated Care solution offerings. We received a sale price of $227 million, which is subject to post-closing adjustments for working capital and certain other adjustments. The following table presents a reconciliation of the sale price to the net gain recognized on the disposed business operations which is included in "Gain on sale of businesses" in our condensed consolidated statements of operations: (In thousands) Sale price $ 226,623 Net assets/(liabilities) removed (7,617) Transaction expenses (5,573) Foreign currency 1,263 Gain on sale of businesses $ 214,696 The following table presents a reconciliation of the sale price to the cash proceeds received from CGM which are included in "Sale of businesses" in our condensed consolidated statements of cash flows: (In thousands) Sale price $ 226,623 VAT and other transaction taxes, net (2,142) Cash received from sale of businesses $ 224,481 Amounts included in our condensed consolidated balance sheets related to the disposed business operations immediately prior to the sale on July 1, 2020 were as follows: (In thousands) Asset/(Liability) Receivables, net $ 7,334 Inventory 65 Prepaid expenses and other 5,759 Property and equipment, net 336 Right-of-use assets 554 Software development costs, net 5,532 Goodwill 7,692 Intangible assets, net 3,687 Accounts payable (1,631) Deferred revenue (16,655) Accrued payroll and tax withholdings (4,545) Other current liabilities (511) Net assets/(liabilities) $ 7,617 Revenue Cycle Outsourcing On August 3, 2020, we sold certain of our revenue cycle outsourcing business operations to affiliates of R1 RCM Inc., as a part of our portfolio management strategy. Such operations included the associates, client contracts, certain other assets, and certain liabilities related to our commercial revenue cycle outsourcing services business. A net gain of $2 million was recognized on the disposed business operations and is included in "Gain on sale of businesses" in our condensed consolidated statements of operations. Amounts included in our condensed consolidated balance sheets related to the disposed business operations immediately prior to the sale on August 3, 2020 were not material to our condensed consolidated financial statements. |
Income Taxes
Income Taxes | 9 Months Ended |
Sep. 30, 2020 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income TaxesWe determine the tax provision for interim periods using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter we update our estimate of the annual effective tax rate, and if our estimated tax rate changes, we make a cumulative adjustment. Our effective tax rate was 21.7% and 18.9% for the first nine months of 2020 and 2019, respectively. The increase in the effective tax rate in the first nine months of 2020 is primarily due to a decrease in net excess tax benefits recognized as a component of income tax expense in connection with the exercise of stock options and the vesting of restricted share and share unit awards. Also contributing to the increase, are taxes associated with the divestiture transactions that closed in the third quarter of 2020, as further discussed in Note (7). |
Earnings Per Share
Earnings Per Share | 9 Months Ended |
Sep. 30, 2020 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | Earnings Per Share A reconciliation of the numerators and the denominators of the basic and diluted per share computations are as follows: Three Months Ended 2020 2019 Earnings Shares Per-Share Earnings Shares Per-Share (In thousands, except per share data) (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount Basic earnings per share: Income available to common shareholders $ 356,676 305,759 $ 1.17 $ 81,935 315,876 $ 0.26 Effect of dilutive securities: Stock options, non-vested shares and share units — 2,607 — 3,237 Diluted earnings per share: Income available to common shareholders including assumed conversions $ 356,676 308,366 $ 1.16 $ 81,935 319,113 $ 0.26 For the three months ended September 30, 2020 and September 28, 2019, options to purchase 3.9 million and 7.7 million shares of common stock at per share prices ranging from $55.24 to $76.49 and $54.87 to $75.83, respectively, were outstanding but were not included in the computation of diluted earnings per share because they were anti-dilutive. Nine Months Ended 2020 2019 Earnings Shares Per-Share Earnings Shares Per-Share (In thousands, except per share data) (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount Basic earnings per share: Income available to common shareholders $ 638,583 306,759 $ 2.08 $ 375,123 320,282 $ 1.17 Effect of dilutive securities: Stock options, non-vested shares and share units — 2,365 — 3,079 Diluted earnings per share: Income available to common shareholders including assumed conversions $ 638,583 309,124 $ 2.07 $ 375,123 323,361 $ 1.16 For the nine months ended September 30, 2020 and September 28, 2019, options to purchase 4.4 million and 10.1 million shares of common stock at per share prices ranging from $52.32 to $76.49 and $51.87 to $75.83, respectively, were outstanding but were not included in the computation of diluted earnings per share because they were anti-dilutive. |
Share-Based Compensation
Share-Based Compensation | 9 Months Ended |
Sep. 30, 2020 | |
Share-based Payment Arrangement [Abstract] | |
Shareholders' Equity and Share-based Payments | Share-Based Compensation and Equity Stock Options Stock option activity for the nine months ended September 30, 2020 was as follows: (In thousands, except per share and term data) Number of Weighted- Aggregate Weighted-Average Outstanding at beginning of year 15,416 $ 56.36 Granted 3 72.36 Exercised (4,009) 50.67 Forfeited and expired (228) 61.32 Outstanding as of September 30, 2020 11,182 58.31 $ 156,372 5.70 Exercisable as of September 30, 2020 7,248 $ 56.87 $ 111,738 4.85 The weighted-average assumptions used to estimate the fair value, under the Black-Scholes-Merton pricing model, of stock options granted during the nine months ended September 30, 2020 were as follows: Expected volatility (%) 24.5 % Expected dividend rate (%) 1 % Expected term (yrs) 6 Risk-free rate (%) 1.1 % Fair value per option $ 16.64 As of September 30, 2020, there was $58 million of total unrecognized compensation cost related to stock options granted under all plans. That cost is expected to be recognized over a weighted-average period of 2.12 years. Non-vested Shares and Share Units Non-vested share and share unit activity for the nine months ended September 30, 2020 was as follows: (In thousands, except per share data) Number of Shares Weighted-Average Outstanding at beginning of year 2,634 $ 65.30 Granted 2,520 69.99 Vested (946) 66.30 Forfeited (97) 67.24 Outstanding as of September 30, 2020 4,111 $ 67.90 As of September 30, 2020, there was $223 million of total unrecognized compensation cost related to non-vested share and share unit awards granted under all plans. That cost is expected to be recognized over a weighted-average period of 1.96 years. Share-Based Compensation Cost The following table presents total compensation expense recognized with respect to stock options, non-vested shares and share units, and our associate stock purchase plan: Three Months Ended Nine Months Ended (In thousands) 2020 2019 2020 2019 Stock option and non-vested share and share unit compensation expense $ 37,920 $ 30,537 $ 110,500 $ 73,421 Associate stock purchase plan expense 1,367 1,321 4,195 4,612 Amounts capitalized in software development costs, net of amortization (1,150) (76) (2,971) 70 Amounts charged against earnings, before income tax benefit $ 38,137 $ 31,782 $ 111,724 $ 78,103 Amount of related income tax benefit recognized in earnings $ 7,818 $ 6,330 $ 22,452 $ 14,888 Treasury Stock Under our current share repurchase program, which was initially approved by our Board of Directors in May 2017 and most recently amended in December 2019, the Company is authorized to repurchase up to $3.70 billion of shares of our common stock, excluding transaction costs. The repurchases are to be effectuated in the open market, by block purchase, in privately negotiated transactions, or through other transactions managed by broker-dealers. No time limit was set for the completion of the program. During the nine months ended September 30, 2020, we repurchased 9.2 million shares for total consideration of $650 million under the program. The shares were recorded as treasury stock and accounted for under the cost method. No repurchased shares have been retired. As of September 30, 2020, $1.03 billion remains available for repurchase under the program. Dividends On September 10, 2020, our Board of Directors declared a cash dividend of $0.18 per share on our issued and outstanding common stock, which was paid on October 13, 2020 to shareholders of record as of September 25, 2020. On May 21, 2020, our Board of Directors declared a cash dividend of $0.18 per share on our issued and outstanding common stock, which was paid on July 17, 2020 to shareholders of record as of June 5, 2020. On March 19, 2020, our Board of Directors declared a cash dividend of $0.18 per share on our issued and outstanding common stock, which was paid on April 17, 2020 to shareholders of record as of April 3, 2020. In connection with the declaration of such dividends, our non-vested shares and share units are entitled to dividend equivalents, which will be payable to the holder subject to, and upon vesting of, the underlying awards. Our outstanding stock options are not entitled to dividend or dividend equivalents. At both September 30, 2020 and December 28, 2019, our condensed consolidated balance sheets included liabilities for dividends payable of $56 million, which are included in "Other current liabilities". Accumulated Other Comprehensive Loss, Net (AOCI) The components of AOCI, net of tax, were as follows: Foreign currency translation adjustment and other Unrealized loss on cash flow hedge Unrealized holding gain (loss) on available-for-sale investments Total (In thousands) Balance at December 28, 2019 $ (106,347) $ (12,578) $ 265 $ (118,660) Other comprehensive income (loss) before reclassifications (20,546) (20,430) (849) (41,825) Amounts reclassified from AOCI — 1,122 — 1,122 Balance at March 31, 2020 (126,893) (31,886) (584) (159,363) Other comprehensive income (loss) before reclassifications 9,197 (3,205) 1,502 7,494 Amounts reclassified from AOCI — 2,198 — 2,198 Balance at June 30, 2020 (117,696) (32,893) 918 (149,671) Other comprehensive income (loss) before reclassifications 9,611 (289) (220) 9,102 Amounts reclassified from AOCI — 2,554 — 2,554 Balance at September 30, 2020 $ (108,085) $ (30,628) $ 698 $ (138,015) Foreign currency translation adjustment and other Unrealized loss on cash flow hedge Unrealized holding gain (loss) on available-for-sale investments Total (In thousands) Balance at December 29, 2018 $ (102,939) $ — $ (613) $ (103,552) Other comprehensive income (loss) before reclassifications 2,321 — 637 2,958 Amounts reclassified from AOCI — — — — Balance at March 30, 2019 (100,618) — 24 (100,594) Other comprehensive income (loss) before reclassifications (100) (12,223) 216 (12,107) Amounts reclassified from AOCI — (147) — (147) Balance at June 29, 2019 (100,718) (12,370) 240 (112,848) Other comprehensive income (loss) before reclassifications (11,679) (4,135) 17 (15,797) Amounts reclassified from AOCI — 98 (3) 95 Balance at September 28, 2019 $ (112,397) $ (16,407) $ 254 $ (128,550) The effects on net earnings of amounts reclassified from AOCI were as follows: (In thousands) Three Months Ended Nine Months Ended AOCI Component Location 2020 2019 2020 2019 Unrealized loss on cash flow hedge Other income, net $ (3,213) $ (122) $ (7,383) $ 58 Income taxes 659 24 1,509 (9) Net of tax (2,554) (98) (5,874) 49 Unrealized holding gain (loss) on available-for-sale investments Other income, net — 4 — 4 Income taxes — (1) — (1) Net of tax — 3 — 3 Total amount reclassified, net of tax $ (2,554) $ (95) $ (5,874) $ 52 |
Contingencies
Contingencies | 9 Months Ended |
Sep. 30, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
Contingencies Disclosure | Contingencies We accrue estimates for resolution of any legal and other contingencies when losses are probable and reasonably estimable in accordance with ASC 450, Contingencies ("ASC 450"). No less than quarterly, and as facts and circumstances change, we review the status of each significant matter underlying a legal proceeding or claim and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made, which may prove to be incomplete or inaccurate or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. Should any one or a combination of more than one of these proceedings be successful, or should we determine to settle any one or a combination of these matters, we may be required to pay substantial sums, become subject to the entry of an injunction or be forced to change the manner in which we operate our business, which could have a material adverse impact on our business, results of operations, cash flows or financial condition. As previously disclosed, we continue to be in dispute with Fujitsu Services Limited ("Fujitsu") regarding Fujitsu's obligation to pay amounts to us due upon the termination of a subcontract, including client receivables, in connection with Fujitsu's contract as the prime contractor in the National Health Service ("NHS") initiative to automate clinical processes and digitize medical records in the Southern region of England. The NHS terminated its contract with Fujitsu, which gave rise to the termination of our subcontract with Fujitsu. We filed a request for arbitration with the London Court of International Arbitration on April 22, 2019 seeking damages. On December 30, 2019, Fujitsu filed its Defense and Counterclaim (the "Counterclaim") in response. In its Counterclaim, Fujitsu defends against our claim in full and argues that we are liable to Fujitsu for: (i) £306 million in damages based on our alleged fraudulent misrepresentations inducing Fujitsu to enter into the subcontract; or (ii) alternatively, £173.8 million in damages based on our alleged breaches of the subcontract. We filed our response to Fujitsu's Counterclaim on May 1, 2020, to which they have now responded. We believe that Fujitsu's claims are without merit and will vigorously defend against them, and we continue to believe that we have valid and equitable grounds for recovery of the disputed client receivables; however, there can be no assurances as to the outcome of the dispute. As previously disclosed, we recorded a pre-tax charge of $45 million in the fourth quarter of 2018 to provide an allowance against the disputed client receivables reflecting the uncertainty in collection of such receivables and related litigation risk resulting from the conclusion of the non-binding alternative dispute resolution procedures, which occurred before we filed our request for arbitration. We have not concluded that a loss related to the new claims raised by Fujitsu in the Counterclaim is probable, nor have we accrued a liability related to these claims beyond the previously reported pre-tax charge recorded in the fourth quarter of 2018. Although we believe a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss with respect to the Counterclaim given that the dispute is in the early stages of the arbitration process. Arbitration is currently scheduled to occur in April 2022. Cerner Health Services, Inc. ("Cerner HS"), a wholly owned subsidiary of Cerner Corporation, filed a lawsuit in the Chester County, Pennsylvania, Court of Common Pleas against NextGen Healthcare Information Systems, LLC ("NextGen") relating to a dispute arising out of a supplier relationship initially established between Siemens Health Services, Inc. ("Health Services") and NextGen prior to the acquisition of the assets of Health Services by Cerner HS in 2015. In September 2017, the court issued a preliminary injunction to prevent NextGen from refusing to honor certain contractual obligations to support Cerner HS's clients who use NextGen ambulatory EHR solutions. In September 2018, NextGen filed a counterclaim alleging breach of contract and tortious interference but did not specify its damages. In August 2019, NextGen provided an expert report alleging profit disgorgement damages of $135 million or, alternatively, $30.5 million in lost profit damages, but the report did not discuss how our actions allegedly caused NextGen's damages. In December 2019, we deposed NextGen's expert, gaining additional clarity on categories of alleged damages but not on the alleged theories of liability. A jury trial is set to begin on January 25, 2021. We believe NextGen's claims are without merit and will vigorously defend against them; however, there can be no assurances as to the outcome of the dispute. We have not concluded that a loss related to the claims raised by NextGen in its counterclaim is probable, nor have we accrued a liability related to these claims. Although a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss in light of the inherent difficulty of predicting the outcome of litigation generally, the wide range of damages presented by NextGen's expert, and the continued lack of clarity on the causal connection between Cerner Corporation's and Cerner HS's actions and any alleged damages. The terms of our agreements with our clients generally provide for limited indemnification of such clients against losses, expenses and liabilities arising from third party or other claims based on, among other things, alleged infringement by our solutions of an intellectual property right of third parties or damages caused by data privacy breaches or system interruptions. The terms of such indemnification often limit the scope of and remedies for such indemnification obligations and generally include, as applicable, a right to replace or modify an infringing solution. For several reasons, including the lack of a sufficient number of prior indemnification claims relating to IP infringement, data privacy breaches or system interruptions, the inherent uncertainty stemming from such claims, and the lack of a monetary liability limit for such claims under the terms of the corresponding agreements with our clients, we cannot determine the maximum amount of potential future payments, if any, related to such indemnification provisions. In addition to commitments and obligations in the ordinary course of business, we are involved in various other legal proceedings and claims that arise in the ordinary course of business, including for example, employment and client disputes and litigation alleging solution and implementation defects, personal injury, intellectual property infringement, violations of law, breaches of contract and warranties, and compliance audits by various government agencies. Many of these proceedings are at preliminary stages and many seek an indeterminate amount of damages. At this time, we do not believe the range of potential losses under any claims to be material to our consolidated financial statements. |
Segment Reporting
Segment Reporting | 9 Months Ended |
Sep. 30, 2020 | |
Segment Reporting [Abstract] | |
Segment Reporting | Segment ReportingWe have two operating segments, Domestic and International. Revenues are derived primarily from the sale of clinical, financial and administrative information solutions and services. The cost of revenues includes the cost of third-party consulting services, computer hardware, devices and sublicensed software purchased from manufacturers for delivery to clients. It also includes the cost of hardware maintenance and sublicensed software support subcontracted to the manufacturers. Operating expenses incurred by the geographic business segments consist of sales and client service expenses including salaries of sales and client service personnel, expenses associated with our managed services business, marketing expenses, communications expenses and unreimbursed travel expenses. "Other" includes expenses that have not been allocated to the operating segments, such as software development, general and administrative expenses, certain organizational restructuring and other expense, share-based compensation expense, and certain amortization and depreciation. "Other" also includes gains or losses recognized on the divestiture of businesses. Performance of the segments is assessed at the operating earnings level by our chief operating decision maker, who is our Chief Executive Officer. Items such as interest, income taxes, capital expenditures and total assets are managed at the consolidated level and thus are not included in our operating segment disclosures. Accounting policies for each of the reportable segments are the same as those used on a consolidated basis. The following table presents a summary of our operating segments and other expense for the three and nine months ended September 30, 2020 and September 28, 2019: (In thousands) Domestic International Other Total Three Months Ended 2020 Revenues $ 1,230,769 $ 137,904 $ — $ 1,368,673 Costs of revenue 219,938 11,951 — 231,889 Operating expenses 566,777 58,626 316,430 941,833 Total costs and expenses 786,715 70,577 316,430 1,173,722 Gain on sale of businesses — — 216,869 216,869 Operating earnings (loss) $ 444,054 $ 67,327 $ (99,561) $ 411,820 (In thousands) Domestic International Other Total Three Months Ended 2019 Revenues $ 1,265,263 $ 164,165 $ — $ 1,429,428 Costs of revenue 246,634 25,144 — 271,778 Operating expenses 639,590 68,153 361,130 1,068,873 Total costs and expenses 886,224 93,297 361,130 1,340,651 Operating earnings (loss) $ 379,039 $ 70,868 $ (361,130) $ 88,777 (In thousands) Domestic International Other Total Nine Months Ended 2020 Revenues $ 3,645,397 $ 465,366 $ — $ 4,110,763 Costs of revenue 638,284 59,984 — 698,268 Operating expenses 1,724,545 182,594 985,131 2,892,270 Total costs and expenses 2,362,829 242,578 985,131 3,590,538 Gain on sale of businesses — — 216,869 216,869 Operating earnings (loss) $ 1,282,568 $ 222,788 $ (768,262) $ 737,094 (In thousands) Domestic International Other Total Nine Months Ended 2019 Revenues $ 3,762,205 $ 488,161 $ — $ 4,250,366 Costs of revenue 719,119 74,536 — 793,655 Operating expenses 1,817,244 209,580 1,012,049 3,038,873 Total costs and expenses 2,536,363 284,116 1,012,049 3,832,528 Operating earnings (loss) $ 1,225,842 $ 204,045 $ (1,012,049) $ 417,838 |
Organization, Consolidation and
Organization, Consolidation and Presentation of Financial Statements (Policies) | 9 Months Ended |
Sep. 30, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | The condensed consolidated financial statements were prepared using GAAP |
Fiscal Period, Policy [Policy Text Block] | Prior to fiscal year 2020, our third fiscal quarter ended on the Saturday closest to September 30. The third quarter and year-to-date periods for 2019 presented herein consisted of 91 days and 273 days, respectively, and ended on September 28, 2019. In December 2019, our Board of Directors approved the change of our fiscal year to a calendar year, commencing with fiscal year 2020. Accordingly, the third quarter and year-to-date periods for 2020 presented herein consisted of 92 days and 277 days, respectively, and ended on September 30, 2020. All references to periods in these notes to condensed consolidated financial statements represent the respective periods described above ending on September 30, 2020 and September 28, 2019, unless otherwise noted. |
Revenue from Contracts with C_2
Revenue from Contracts with Customers (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Revenue from Contract with Customer [Abstract] | |
Disaggregation of Revenue [Table Text Block] | Disaggregation of Revenue The following tables present revenues disaggregated by our business models: Three Months Ended 2020 2019 (In thousands) Domestic International Total Domestic International Total Licensed software $ 159,327 $ 12,367 $ 171,694 $ 144,599 $ 9,934 $ 154,533 Technology resale 45,217 1,896 47,113 65,103 5,072 70,175 Subscriptions 87,878 5,529 93,407 85,230 6,674 91,904 Professional services 433,127 46,768 479,895 446,562 60,893 507,455 Managed services 280,827 31,017 311,844 272,933 29,502 302,435 Support and maintenance 219,682 40,296 259,978 227,131 50,163 277,294 Reimbursed travel 4,711 31 4,742 23,705 1,927 25,632 Total revenues $ 1,230,769 $ 137,904 $ 1,368,673 $ 1,265,263 $ 164,165 $ 1,429,428 Nine Months Ended 2020 2019 (In thousands) Domestic Segment International Segment Total Domestic Segment International Segment Total Licensed software $ 444,774 $ 37,114 $ 481,888 $ 466,105 $ 40,018 $ 506,123 Technology resale 126,042 14,675 140,717 169,112 17,338 186,450 Subscriptions 260,095 19,749 279,844 246,505 19,460 265,965 Professional services 1,295,759 156,564 1,452,323 1,313,701 169,500 1,483,201 Managed services 836,242 92,114 928,356 818,818 85,661 904,479 Support and maintenance 663,399 144,296 807,695 679,214 151,454 830,668 Reimbursed travel 19,086 854 19,940 68,750 4,730 73,480 Total revenues $ 3,645,397 $ 465,366 $ 4,110,763 $ 3,762,205 $ 488,161 $ 4,250,366 The following tables present our revenues disaggregated by timing of revenue recognition: Three Months Ended 2020 2019 (In thousands) Domestic International Total Domestic International Total Revenue recognized over time $ 1,143,515 $ 132,891 $ 1,276,406 $ 1,143,470 $ 155,017 $ 1,298,487 Revenue recognized at a point in time 87,254 5,013 92,267 121,793 9,148 130,941 Total revenues $ 1,230,769 $ 137,904 $ 1,368,673 $ 1,265,263 $ 164,165 $ 1,429,428 Nine Months Ended 2020 2019 (In thousands) Domestic Segment International Segment Total Domestic Segment International Segment Total Revenue recognized over time $ 3,410,827 $ 437,791 $ 3,848,618 $ 3,403,965 $ 445,320 $ 3,849,285 Revenue recognized at a point in time 234,570 27,575 262,145 358,240 42,841 401,081 Total revenues $ 3,645,397 $ 465,366 $ 4,110,763 $ 3,762,205 $ 488,161 $ 4,250,366 |
Receivables (Tables)
Receivables (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Receivables [Abstract] | |
Summary of Net Receivables | A summary of net receivables is as follows: (In thousands) September 30, 2020 December 28, 2019 Client receivables $ 1,370,394 $ 1,245,670 Less: Provision for expected credit losses 151,167 106,075 Total receivables, net $ 1,219,227 $ 1,139,595 |
Accounts Receivable, Allowance for Credit Loss | A reconciliation of the beginning and ending amount of our provision for expected credit losses is as follows: (In thousands) Provision for expected credit losses - balance at December 28, 2019 $ 106,075 Cumulative effect of accounting change (ASU 2016-13) 4,606 Additions charged to costs and expenses 54,636 Deductions (14,150) Provision for expected credit losses - balance at September 30, 2020 $ 151,167 |
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] | A summary of such cumulative effect adjustment is as follows: (In thousands) Increase/(Decrease) Receivables, net $ (4,606) Retained earnings (4,606) |
Investments (Tables)
Investments (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Investments [Abstract] | |
Schedule of available-for-sale investments | Available-for-sale investments at September 30, 2020 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 56,855 $ — $ — $ 56,855 Time deposits 19,676 — — 19,676 Commercial Paper 1,600 — — 1,600 Government and corporate bonds 1,150 — — 1,150 Total cash equivalents 79,281 — — 79,281 Short-term investments: Time deposits 21,248 — — 21,248 Commercial paper 259,000 22 (7) 259,015 Government and corporate bonds 192,536 559 (35) 193,060 Total short-term investments 472,784 581 (42) 473,323 Long-term investments: Government and corporate bonds 91,605 180 (78) 91,707 Total available-for-sale investments $ 643,670 $ 761 $ (120) $ 644,311 Available-for-sale investments at December 28, 2019 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 185,666 $ — $ — $ 185,666 Time deposits 64,286 — — 64,286 Total cash equivalents 249,952 — — 249,952 Short-term investments: Time deposits 2,506 — — 2,506 Government and corporate bonds 83,272 52 (11) 83,313 Total short-term investments 85,778 52 (11) 85,819 Long-term investments: Government and corporate bonds 96,186 91 (67) 96,210 Total available-for-sale investments $ 431,916 $ 143 $ (78) $ 431,981 |
Debt (Tables)
Debt (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Debt Disclosure [Abstract] | |
Schedule of Debt | The following is a summary of indebtedness outstanding: (In thousands) September 30, 2020 December 28, 2019 Credit agreement loans due May 5, 2024 $ 600,000 $ 600,000 Senior notes: Series 2020-A due March 11, 2030 300,000 — Series 2015-A due February 15, 2022 225,000 225,000 Series 2015-B due February 14, 2025 200,000 200,000 Other 11,662 14,162 Total indebtedness 1,336,662 1,039,162 Less: debt issuance costs (644) (780) Long-term debt $ 1,336,018 $ 1,038,382 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Fair Value Disclosures [Abstract] | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis | The following table details our investments in available-for-sale debt securities measured and recorded at fair value on a recurring basis at September 30, 2020: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 56,855 $ — $ — Time deposits Cash equivalents — 19,676 — Commercial paper Cash equivalents — 1,600 — Government and corporate bonds Cash equivalents — 1,150 — Time deposits Short-term investments — 21,248 — Commercial paper Short-term investments — 259,015 — Government and corporate bonds Short-term investments — 193,060 — Government and corporate bonds Long-term investments — 91,707 — The following table details our investments in available-for-sale debt securities measured and recorded at fair value on a recurring basis at December 28, 2019: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 185,666 $ — $ — Time deposits Cash equivalents — 64,286 — Time deposits Short-term investments — 2,506 — Government and corporate bonds Short-term investments — 83,313 — Government and corporate bonds Long-term investments — 96,210 — |
Gain on Sale of Businesses (Tab
Gain on Sale of Businesses (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Disposal Groups, Including Discontinued Operations | The following table presents a reconciliation of the sale price to the net gain recognized on the disposed business operations which is included in "Gain on sale of businesses" in our condensed consolidated statements of operations: (In thousands) Sale price $ 226,623 Net assets/(liabilities) removed (7,617) Transaction expenses (5,573) Foreign currency 1,263 Gain on sale of businesses $ 214,696 The following table presents a reconciliation of the sale price to the cash proceeds received from CGM which are included in "Sale of businesses" in our condensed consolidated statements of cash flows: (In thousands) Sale price $ 226,623 VAT and other transaction taxes, net (2,142) Cash received from sale of businesses $ 224,481 Amounts included in our condensed consolidated balance sheets related to the disposed business operations immediately prior to the sale on July 1, 2020 were as follows: (In thousands) Asset/(Liability) Receivables, net $ 7,334 Inventory 65 Prepaid expenses and other 5,759 Property and equipment, net 336 Right-of-use assets 554 Software development costs, net 5,532 Goodwill 7,692 Intangible assets, net 3,687 Accounts payable (1,631) Deferred revenue (16,655) Accrued payroll and tax withholdings (4,545) Other current liabilities (511) Net assets/(liabilities) $ 7,617 |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 3 Months Ended | 9 Months Ended |
Sep. 30, 2020 | Sep. 30, 2020 | |
Earnings Per Share [Abstract] | ||
Reconciliation Of The Numerators And The Denominators Of The Basic And Diluted Per Share | A reconciliation of the numerators and the denominators of the basic and diluted per share computations are as follows: Three Months Ended 2020 2019 Earnings Shares Per-Share Earnings Shares Per-Share (In thousands, except per share data) (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount Basic earnings per share: Income available to common shareholders $ 356,676 305,759 $ 1.17 $ 81,935 315,876 $ 0.26 Effect of dilutive securities: Stock options, non-vested shares and share units — 2,607 — 3,237 Diluted earnings per share: Income available to common shareholders including assumed conversions $ 356,676 308,366 $ 1.16 $ 81,935 319,113 $ 0.26 | Nine Months Ended 2020 2019 Earnings Shares Per-Share Earnings Shares Per-Share (In thousands, except per share data) (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount Basic earnings per share: Income available to common shareholders $ 638,583 306,759 $ 2.08 $ 375,123 320,282 $ 1.17 Effect of dilutive securities: Stock options, non-vested shares and share units — 2,365 — 3,079 Diluted earnings per share: Income available to common shareholders including assumed conversions $ 638,583 309,124 $ 2.07 $ 375,123 323,361 $ 1.16 |
Share-Based Compensation (Table
Share-Based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Share-based Payment Arrangement [Abstract] | |
Schedule Of Stock Options Activity | Stock option activity for the nine months ended September 30, 2020 was as follows: (In thousands, except per share and term data) Number of Weighted- Aggregate Weighted-Average Outstanding at beginning of year 15,416 $ 56.36 Granted 3 72.36 Exercised (4,009) 50.67 Forfeited and expired (228) 61.32 Outstanding as of September 30, 2020 11,182 58.31 $ 156,372 5.70 Exercisable as of September 30, 2020 7,248 $ 56.87 $ 111,738 4.85 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions | The weighted-average assumptions used to estimate the fair value, under the Black-Scholes-Merton pricing model, of stock options granted during the nine months ended September 30, 2020 were as follows: Expected volatility (%) 24.5 % Expected dividend rate (%) 1 % Expected term (yrs) 6 Risk-free rate (%) 1.1 % Fair value per option $ 16.64 |
Schedule of Share-based Compensation, Restricted Stock Activity | Non-vested share and share unit activity for the nine months ended September 30, 2020 was as follows: (In thousands, except per share data) Number of Shares Weighted-Average Outstanding at beginning of year 2,634 $ 65.30 Granted 2,520 69.99 Vested (946) 66.30 Forfeited (97) 67.24 Outstanding as of September 30, 2020 4,111 $ 67.90 |
Compensation Expense Recognized In The Condensed Consolidated Statements Of Operations | The following table presents total compensation expense recognized with respect to stock options, non-vested shares and share units, and our associate stock purchase plan: Three Months Ended Nine Months Ended (In thousands) 2020 2019 2020 2019 Stock option and non-vested share and share unit compensation expense $ 37,920 $ 30,537 $ 110,500 $ 73,421 Associate stock purchase plan expense 1,367 1,321 4,195 4,612 Amounts capitalized in software development costs, net of amortization (1,150) (76) (2,971) 70 Amounts charged against earnings, before income tax benefit $ 38,137 $ 31,782 $ 111,724 $ 78,103 Amount of related income tax benefit recognized in earnings $ 7,818 $ 6,330 $ 22,452 $ 14,888 |
Schedule of Accumulated Other Comprehensive Income (Loss) | The components of AOCI, net of tax, were as follows: Foreign currency translation adjustment and other Unrealized loss on cash flow hedge Unrealized holding gain (loss) on available-for-sale investments Total (In thousands) Balance at December 28, 2019 $ (106,347) $ (12,578) $ 265 $ (118,660) Other comprehensive income (loss) before reclassifications (20,546) (20,430) (849) (41,825) Amounts reclassified from AOCI — 1,122 — 1,122 Balance at March 31, 2020 (126,893) (31,886) (584) (159,363) Other comprehensive income (loss) before reclassifications 9,197 (3,205) 1,502 7,494 Amounts reclassified from AOCI — 2,198 — 2,198 Balance at June 30, 2020 (117,696) (32,893) 918 (149,671) Other comprehensive income (loss) before reclassifications 9,611 (289) (220) 9,102 Amounts reclassified from AOCI — 2,554 — 2,554 Balance at September 30, 2020 $ (108,085) $ (30,628) $ 698 $ (138,015) Foreign currency translation adjustment and other Unrealized loss on cash flow hedge Unrealized holding gain (loss) on available-for-sale investments Total (In thousands) Balance at December 29, 2018 $ (102,939) $ — $ (613) $ (103,552) Other comprehensive income (loss) before reclassifications 2,321 — 637 2,958 Amounts reclassified from AOCI — — — — Balance at March 30, 2019 (100,618) — 24 (100,594) Other comprehensive income (loss) before reclassifications (100) (12,223) 216 (12,107) Amounts reclassified from AOCI — (147) — (147) Balance at June 29, 2019 (100,718) (12,370) 240 (112,848) Other comprehensive income (loss) before reclassifications (11,679) (4,135) 17 (15,797) Amounts reclassified from AOCI — 98 (3) 95 Balance at September 28, 2019 $ (112,397) $ (16,407) $ 254 $ (128,550) |
Reclassification out of Accumulated Other Comprehensive Income | The effects on net earnings of amounts reclassified from AOCI were as follows: (In thousands) Three Months Ended Nine Months Ended AOCI Component Location 2020 2019 2020 2019 Unrealized loss on cash flow hedge Other income, net $ (3,213) $ (122) $ (7,383) $ 58 Income taxes 659 24 1,509 (9) Net of tax (2,554) (98) (5,874) 49 Unrealized holding gain (loss) on available-for-sale investments Other income, net — 4 — 4 Income taxes — (1) — (1) Net of tax — 3 — 3 Total amount reclassified, net of tax $ (2,554) $ (95) $ (5,874) $ 52 |
Segment Reporting (Tables)
Segment Reporting (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Segment Reporting [Abstract] | |
Summary of the Operating Information | The following table presents a summary of our operating segments and other expense for the three and nine months ended September 30, 2020 and September 28, 2019: (In thousands) Domestic International Other Total Three Months Ended 2020 Revenues $ 1,230,769 $ 137,904 $ — $ 1,368,673 Costs of revenue 219,938 11,951 — 231,889 Operating expenses 566,777 58,626 316,430 941,833 Total costs and expenses 786,715 70,577 316,430 1,173,722 Gain on sale of businesses — — 216,869 216,869 Operating earnings (loss) $ 444,054 $ 67,327 $ (99,561) $ 411,820 (In thousands) Domestic International Other Total Three Months Ended 2019 Revenues $ 1,265,263 $ 164,165 $ — $ 1,429,428 Costs of revenue 246,634 25,144 — 271,778 Operating expenses 639,590 68,153 361,130 1,068,873 Total costs and expenses 886,224 93,297 361,130 1,340,651 Operating earnings (loss) $ 379,039 $ 70,868 $ (361,130) $ 88,777 (In thousands) Domestic International Other Total Nine Months Ended 2020 Revenues $ 3,645,397 $ 465,366 $ — $ 4,110,763 Costs of revenue 638,284 59,984 — 698,268 Operating expenses 1,724,545 182,594 985,131 2,892,270 Total costs and expenses 2,362,829 242,578 985,131 3,590,538 Gain on sale of businesses — — 216,869 216,869 Operating earnings (loss) $ 1,282,568 $ 222,788 $ (768,262) $ 737,094 (In thousands) Domestic International Other Total Nine Months Ended 2019 Revenues $ 3,762,205 $ 488,161 $ — $ 4,250,366 Costs of revenue 719,119 74,536 — 793,655 Operating expenses 1,817,244 209,580 1,012,049 3,038,873 Total costs and expenses 2,536,363 284,116 1,012,049 3,832,528 Operating earnings (loss) $ 1,225,842 $ 204,045 $ (1,012,049) $ 417,838 |
Policies (Details)
Policies (Details) | 9 Months Ended |
Sep. 30, 2020 | |
Interim Statement Presentation [Line Items] | |
Basis of Accounting, Policy [Policy Text Block] | The condensed consolidated financial statements were prepared using GAAP |
Use of Estimates, Policy [Policy Text Block] | These principles require us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses |
Fiscal Period, Policy [Policy Text Block] | Prior to fiscal year 2020, our third fiscal quarter ended on the Saturday closest to September 30. The third quarter and year-to-date periods for 2019 presented herein consisted of 91 days and 273 days, respectively, and ended on September 28, 2019. In December 2019, our Board of Directors approved the change of our fiscal year to a calendar year, commencing with fiscal year 2020. Accordingly, the third quarter and year-to-date periods for 2020 presented herein consisted of 92 days and 277 days, respectively, and ended on September 30, 2020. All references to periods in these notes to condensed consolidated financial statements represent the respective periods described above ending on September 30, 2020 and September 28, 2019, unless otherwise noted. |
Description of New Accounting Pronouncements Not yet Adopted [Text Block] | In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform, such as the upcoming discontinuance of the London Interbank Offered Rate ("LIBOR"). The accommodations within ASU 2020-04 may be applied prospectively from the beginning of our 2020 first quarter through December 31, 2022. We are currently evaluating the effect that ASU 2020-04 may have on our contracts that reference LIBOR, specifically, our Third Amended and Restated Credit Agreement (as amended, the "Credit Agreement") and related interest rate swap. As of the date of this filing, we have not elected to apply any of the provisions of this standard. |
Accounting Standards Update 2018-18 [Member] | |
Interim Statement Presentation [Line Items] | |
New Accounting Pronouncement or Change in Accounting Principle, Description | In November 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which clarifies when transactions between participants in a collaborative arrangement are within the scope of the FASB's recent revenue standard (Topic 606). Such guidance clarifies revenue recognition and financial statement presentation for transactions between collaboration participants. We adopted ASU 2018-18 in the first quarter of 2020. Such guidance did not have an impact on our consolidated financial statements and related disclosures. |
Interim Statement Presentatio_2
Interim Statement Presentation (Details) $ in Millions | 9 Months Ended |
Sep. 30, 2020USD ($) | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
CARES Act Deferred Remittance of Employer Payroll Tax | $ 56 |
Disaggregation of Revenue (Deta
Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 28, 2019 | Sep. 30, 2020 | Sep. 28, 2019 | |
Disaggregation of Revenue [Line Items] | ||||
Revenues | $ 1,368,673 | $ 1,429,428 | $ 4,110,763 | $ 4,250,366 |
Transferred over Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 1,276,406 | 1,298,487 | 3,848,618 | 3,849,285 |
Transferred at Point in Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 92,267 | 130,941 | 262,145 | 401,081 |
Domestic Segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 1,230,769 | 1,265,263 | 3,645,397 | 3,762,205 |
Domestic Segment | Transferred over Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 1,143,515 | 1,143,470 | 3,410,827 | 3,403,965 |
Domestic Segment | Transferred at Point in Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 87,254 | 121,793 | 234,570 | 358,240 |
International Segment [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 137,904 | 164,165 | 465,366 | 488,161 |
International Segment [Member] | Transferred over Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 132,891 | 155,017 | 437,791 | 445,320 |
International Segment [Member] | Transferred at Point in Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 5,013 | 9,148 | 27,575 | 42,841 |
Sales Revenue, Licensed Software, Net [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 171,694 | 154,533 | 481,888 | 506,123 |
Sales Revenue, Licensed Software, Net [Member] | Domestic Segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 159,327 | 144,599 | 444,774 | 466,105 |
Sales Revenue, Licensed Software, Net [Member] | International Segment [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 12,367 | 9,934 | 37,114 | 40,018 |
Sales Revenue, Technology Resale, Net [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 47,113 | 70,175 | 140,717 | 186,450 |
Sales Revenue, Technology Resale, Net [Member] | Domestic Segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 45,217 | 65,103 | 126,042 | 169,112 |
Sales Revenue, Technology Resale, Net [Member] | International Segment [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 1,896 | 5,072 | 14,675 | 17,338 |
Sales Revenue, Subscriptions, Net [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 93,407 | 91,904 | 279,844 | 265,965 |
Sales Revenue, Subscriptions, Net [Member] | Domestic Segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 87,878 | 85,230 | 260,095 | 246,505 |
Sales Revenue, Subscriptions, Net [Member] | International Segment [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 5,529 | 6,674 | 19,749 | 19,460 |
Sales Revenue, Professional Services, Net [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 479,895 | 507,455 | 1,452,323 | 1,483,201 |
Sales Revenue, Professional Services, Net [Member] | Domestic Segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 433,127 | 446,562 | 1,295,759 | 1,313,701 |
Sales Revenue, Professional Services, Net [Member] | International Segment [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 46,768 | 60,893 | 156,564 | 169,500 |
Sales Revenue, Managed Services, Net [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 311,844 | 302,435 | 928,356 | 904,479 |
Sales Revenue, Managed Services, Net [Member] | Domestic Segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 280,827 | 272,933 | 836,242 | 818,818 |
Sales Revenue, Managed Services, Net [Member] | International Segment [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 31,017 | 29,502 | 92,114 | 85,661 |
Sales Revenue, Support and Maintenance Services, Net [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 259,978 | 277,294 | 807,695 | 830,668 |
Sales Revenue, Support and Maintenance Services, Net [Member] | Domestic Segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 219,682 | 227,131 | 663,399 | 679,214 |
Sales Revenue, Support and Maintenance Services, Net [Member] | International Segment [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 40,296 | 50,163 | 144,296 | 151,454 |
Sales Revenue, Reimbursement Revenue [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 4,742 | 25,632 | 19,940 | 73,480 |
Sales Revenue, Reimbursement Revenue [Member] | Domestic Segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 4,711 | 23,705 | 19,086 | 68,750 |
Sales Revenue, Reimbursement Revenue [Member] | International Segment [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | $ 31 | $ 1,927 | $ 854 | $ 4,730 |
Performance Obligation (Details
Performance Obligation (Details) $ in Millions | 9 Months Ended |
Sep. 30, 2020USD ($) | |
Revenue Recognition [Line Items] | |
Revenue, Remaining Performance Obligation | $ 13,010 |
Contract with Customer, Liability, Revenue Recognized | $ 306 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Explanation | we expect to recognize approximately 30% of the revenue over the next 12 months and the remainder thereafter |
Revenue from Contracts with C_3
Revenue from Contracts with Customers (Details) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 28, 2019 | Sep. 30, 2020 | Sep. 28, 2019 | |
Revenue from Contract with Customer [Abstract] | ||||
Segment Reporting, Disclosure of Major Customers | 19 | 12 | 17 | 11 |
Credit Concentration Risk [Member] | ||||
Revenue from Contract with Customer [Abstract] | ||||
Concentration Risk, Percentage | 14.00% | |||
Concentration Risk [Line Items] | ||||
Concentration Risk, Percentage | 14.00% |
Receivables (Narrative) (Detail
Receivables (Narrative) (Details) - USD ($) $ in Millions | 9 Months Ended | |
Sep. 30, 2020 | Sep. 28, 2019 | |
Receivables [Abstract] | ||
Client cash collections | $ 4,090 | $ 4,230 |
Accounting Standards Update 2016-13 [Member] | ||
Receivables [Abstract] | ||
New Accounting Pronouncement or Change in Accounting Principle, Description | In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which provides a new impairment model for certain financial assets that is based on expected losses rather than incurred losses. Such guidance impacts how we determine our allowance for estimated uncollectible client receivables. The standard requires use of the modified retrospective (cumulative effect) transition approach as of the beginning of the first reporting period in which the guidance was effective, which for the Company was the first quarter of 2020. Under this transition method, the cumulative effect from prior periods upon applying this new guidance was recognized in our condensed consolidated balance sheets as of December 29, 2019. We did not recast comparative periods. | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
New Accounting Pronouncement or Change in Accounting Principle, Description | In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which provides a new impairment model for certain financial assets that is based on expected losses rather than incurred losses. Such guidance impacts how we determine our allowance for estimated uncollectible client receivables. The standard requires use of the modified retrospective (cumulative effect) transition approach as of the beginning of the first reporting period in which the guidance was effective, which for the Company was the first quarter of 2020. Under this transition method, the cumulative effect from prior periods upon applying this new guidance was recognized in our condensed consolidated balance sheets as of December 29, 2019. We did not recast comparative periods. |
Receivables (Summary Of Net Rec
Receivables (Summary Of Net Receivables) (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 28, 2019 |
Receivables [Abstract] | ||
Gross accounts receivable | $ 1,370,394 | $ 1,245,670 |
Less: Allowance for doubtful accounts | 151,167 | 106,075 |
Total receivables, net | $ 1,219,227 | $ 1,139,595 |
Schedule of Valuation and Quali
Schedule of Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2020 | Dec. 28, 2019 | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | ||
Accounts Receivable, Credit Loss Expense (Reversal) | $ 54,636 | |
Accounts Receivable, Allowance for Credit Loss, Writeoff | (14,150) | |
Accounts Receivable, Allowance for Credit Loss | 151,167 | $ 106,075 |
Accounting Standards Update 2016-13 [Member] | Cumulative Effect, Period of Adoption, Adjustment | ||
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | ||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment | $ 4,606 |
Cumulative Effect Transition (D
Cumulative Effect Transition (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 28, 2019 |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Retained Earnings | $ 6,402,220 | $ 5,934,909 |
Receivables, Net | $ 1,219,227 | 1,139,595 |
Accounting Standards Update 2016-13 [Member] | Cumulative Effect, Period of Adoption, Adjustment | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Retained Earnings | (4,606) | |
Receivables, Net | $ (4,606) |
Investments (Narrative) (Detail
Investments (Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2020 | Sep. 30, 2020 | Sep. 28, 2019 | Jun. 30, 2020 | Dec. 28, 2019 | |
Investments [Abstract] | |||||
Proceeds from Sale of Available-for-sale Securities | $ 5 | $ 181 | |||
Equity Securities without Readily Determinable Fair Value, Amount | $ 320 | 320 | $ 314 | ||
Equity Securities, FV-NI | $ 41 | 14 | |||
Equity Securities, FV-NI, Unrealized Gain | 49 | 76 | $ 9 | ||
Equity Method Investments | $ 11 | 11 | $ 9 | ||
Proceeds from Sale of Equity Securities with Readily Determinable Fair Values | $ 90 |
Investments (Details)
Investments (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 28, 2019 |
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | $ 643,670 | $ 431,916 |
Gross Unrealized Gains | 761 | 143 |
Gross Unrealized Losses | (120) | (78) |
Debt Securities, Available-for-sale | 644,311 | 431,981 |
Cash equivalents [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | 79,281 | 249,952 |
Debt Securities, Available-for-sale | 79,281 | 249,952 |
Cash equivalents [Member] | Money market funds [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | 56,855 | 185,666 |
Debt Securities, Available-for-sale | 56,855 | 185,666 |
Cash equivalents [Member] | Time deposits [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | 19,676 | 64,286 |
Debt Securities, Available-for-sale | 19,676 | 64,286 |
Cash equivalents [Member] | Commercial paper [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | 1,600 | |
Debt Securities, Available-for-sale | 1,600 | |
Cash equivalents [Member] | Government and corporate bonds [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | 1,150 | |
Debt Securities, Available-for-sale | 1,150 | |
Short-term investments [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | 472,784 | 85,778 |
Gross Unrealized Gains | 581 | 52 |
Gross Unrealized Losses | (42) | (11) |
Debt Securities, Available-for-sale | 473,323 | 85,819 |
Short-term investments [Member] | Time deposits [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | 21,248 | 2,506 |
Debt Securities, Available-for-sale | 21,248 | 2,506 |
Short-term investments [Member] | Commercial paper [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | 259,000 | |
Gross Unrealized Gains | 22 | |
Gross Unrealized Losses | (7) | |
Debt Securities, Available-for-sale | 259,015 | |
Short-term investments [Member] | Government and corporate bonds [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | 192,536 | 83,272 |
Gross Unrealized Gains | 559 | 52 |
Gross Unrealized Losses | (35) | (11) |
Debt Securities, Available-for-sale | 193,060 | 83,313 |
Long-term investments [Member] | Government and corporate bonds [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | 91,605 | 96,186 |
Gross Unrealized Gains | 180 | 91 |
Gross Unrealized Losses | (78) | (67) |
Debt Securities, Available-for-sale | $ 91,707 | $ 96,210 |
Schedule of Indebtedness Outsta
Schedule of Indebtedness Outstanding (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2020 | Dec. 28, 2019 | |
Debt Instrument [Line Items] | ||
Carrying amount of long-term debt | $ 1,336,662 | $ 1,039,162 |
Debt Issuance Costs, Noncurrent, Net | 644 | 780 |
Long-term Debt | 1,336,018 | 1,038,382 |
Line of Credit | ||
Debt Instrument [Line Items] | ||
Carrying amount of long-term debt | $ 600,000 | 600,000 |
Debt Instrument, Maturity Date | May 5, 2024 | |
Senior Notes - Series 2020-A due March 11, 2030 | ||
Debt Instrument [Line Items] | ||
Carrying amount of long-term debt | $ 300,000 | 0 |
Debt Instrument, Maturity Date | Mar. 11, 2030 | |
Senior Notes - Series 2015 A due February 15, 2022 | ||
Debt Instrument [Line Items] | ||
Carrying amount of long-term debt | $ 225,000 | 225,000 |
Debt Instrument, Maturity Date | Feb. 15, 2022 | |
Senior Notes - Series 2015-B due February 14, 2025 | ||
Debt Instrument [Line Items] | ||
Carrying amount of long-term debt | $ 200,000 | 200,000 |
Debt Instrument, Maturity Date | Feb. 14, 2025 | |
Other | ||
Debt Instrument [Line Items] | ||
Carrying amount of long-term debt | $ 11,662 | $ 14,162 |
Indebtedness (Narrative) (Detai
Indebtedness (Narrative) (Details) - USD ($) $ in Millions | 9 Months Ended | |
Sep. 30, 2020 | Dec. 28, 2019 | |
Debt Instrument [Line Items] | ||
Line of Credit Facility, Interest Rate at Period End | 0.95% | |
General Discussion of Derivative Instruments and Hedging Activities | We are exposed to market risk from fluctuations in the variable interest rates on outstanding indebtedness under our Credit Agreement. In order to manage this exposure, we have entered into an interest rate swap agreement to hedge the variability of cash flows associated with such interest obligations. The interest rate swap is designated as a cash flow hedge, which effectively fixes the interest rate on the hedged indebtedness under our Credit Agreement at 3.06% | |
Derivative, Fair Value, Net | $ 41 | $ 17 |
Debt Instrument, Amount Uncommitted and Available for Sale | 1,500 | |
Senior Notes - Series 2020-A due March 11, 2030 | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Face Amount | $ 300 | |
Debt Instrument, Interest Rate, Stated Percentage | 2.50% | |
Debt Instrument, Maturity Date | Mar. 11, 2030 | |
Debt Instrument, Frequency of Periodic Payment | payable semiannually | |
Debt Instrument, Date of First Required Payment | Sep. 11, 2020 | |
Debt Instrument, Restrictive Covenants | The Series 2020-A Notes are subject to the terms of the 2019 Shelf Agreement, which contains customary events of default and covenants related to limitations on indebtedness and transactions with affiliates and the maintenance of certain financial ratios. |
Fair Value Measurements (Narrat
Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions | 9 Months Ended | |
Sep. 30, 2020 | Dec. 28, 2019 | |
Fair Value Disclosures [Abstract] | ||
Fair Value Measurements, Valuation Processes, Description | We estimate the fair value of our long-term, fixed rate debt using a Level 3 discounted cash flow analysis based on current borrowing rates for debt with similar maturities. We estimate the fair value of our long-term, variable rate debt using a Level 3 discounted cash flow analysis based on LIBOR rate forward curves. | |
Fair value of long-term debt, including current maturities | $ 1,340 | $ 1,070 |
Unsecured Long-term Debt, Noncurrent | $ 1,330 | $ 1,030 |
Fair Value Measurements Fair Va
Fair Value Measurements Fair Value, Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 28, 2019 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | $ 644,311 | $ 431,981 |
Level 1 [Member] | Money market funds [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 56,855 | 185,666 |
Level 2 [Member] | Time deposits [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 19,676 | 64,286 |
Level 2 [Member] | Commercial paper [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 1,600 | |
Level 2 [Member] | Government and corporate bonds [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 1,150 | |
Level 3 [Member] | Money market funds [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 0 | 0 |
Level 3 [Member] | Time deposits [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 0 | 0 |
Short-term investments [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 473,323 | 85,819 |
Short-term investments [Member] | Level 2 [Member] | Time deposits [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 21,248 | 2,506 |
Short-term investments [Member] | Level 2 [Member] | Commercial paper [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 259,015 | |
Short-term investments [Member] | Level 2 [Member] | Government and corporate bonds [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 193,060 | 83,313 |
Short-term investments [Member] | Level 3 [Member] | Time deposits [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Short-term investments [Member] | Level 3 [Member] | Commercial paper [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | |
Short-term investments [Member] | Level 3 [Member] | Government and corporate bonds [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Long-term investments [Member] | Level 2 [Member] | Government and corporate bonds [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 91,707 | 96,210 |
Long-term investments [Member] | Level 3 [Member] | Government and corporate bonds [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | $ 0 | $ 0 |
Gain on Sale of Businesses (Det
Gain on Sale of Businesses (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2020 | Sep. 28, 2019 | Sep. 30, 2020 | Sep. 28, 2019 | Jul. 01, 2020 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Sale of businesses | $ 229,471 | $ 0 | |||
Gain on sale of businesses | $ 216,869 | $ 0 | $ 216,869 | $ 0 | |
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | CompuGroup Medical SE & Co. KGaA [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net | $ 7,334 | ||||
Disposal Group, Including Discontinued Operation, Inventory, Current | 65 | ||||
Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current | 5,759 | ||||
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current | 336 | ||||
Disposal Group, Including Discontinued Operation, Right-of-Use Asset | 554 | ||||
Disposal Group, Including Discontinued Operation, Capitalized Computer Software, Net | 5,532 | ||||
Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent | 7,692 | ||||
Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent | 3,687 | ||||
Disposal Group, Including Discontinued Operation, Accounts Payable, Current | (1,631) | ||||
Disposal Group, Including Discontinued Operation, Deferred Revenue, Noncurrent | (16,655) | ||||
Disposal Group, Including Discontinued Operation, Employee-related Liabilities, Current | (4,545) | ||||
Disposal Group, Including Discontinued Operation, Other Liabilities, Current | (511) | ||||
Disposal Group, Including Discontinued Operation, Consideration | 226,623 | ||||
Disposal Group, Including Discontinue Operation, Net Assets/(Liabilities) | (7,617) | ||||
VAT and other transaction taxes, net | (2,142) | ||||
Sale of businesses | 224,481 | ||||
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | CompuGroup Medical SE & Co. KGaA [Member] | Gain on sale of businesses [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Disposal Group, Including Discontinued Operation, Consideration | 226,623 | ||||
Disposal Group, Including Discontinue Operation, Net Assets/(Liabilities) | $ (7,617) | ||||
Transaction Expenses | (5,573) | ||||
Foreign Currency Adjustment | 1,263 | ||||
Gain on sale of businesses | 214,696 | ||||
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | R1 RCM Inc. [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Gain on sale of businesses | $ 2,000 |
Gain on Sale of Businesses (Nar
Gain on Sale of Businesses (Narrative) (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2020 | Sep. 28, 2019 | Sep. 30, 2020 | Sep. 28, 2019 | Jul. 01, 2020 | |
Discontinued Operations and Disposal Groups [Abstract] | |||||
Gain on sale of businesses | $ 216,869 | $ 0 | $ 216,869 | $ 0 | |
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | CompuGroup Medical SE & Co. KGaA [Member] | |||||
Discontinued Operations and Disposal Groups [Abstract] | |||||
Disposal Group, Including Discontinued Operation, Description and Timing of Disposal | On July 1, 2020, we sold certain of our business operations, primarily conducted in Germany and Spain, to affiliates of CompuGroup Medical SE & Co. KGaA ("CGM"), as a part of our portfolio management strategy. Such operations included the associates, intellectual property, client contracts, other assets, and liabilities related to our medico®, Selene®, Soarian Health Archive®, and Soarian® Integrated Care solution offerings. | ||||
Disposal Group, Including Discontinued Operation, Consideration | $ 226,623 | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Disposal Group, Including Discontinued Operation, Description and Timing of Disposal | On July 1, 2020, we sold certain of our business operations, primarily conducted in Germany and Spain, to affiliates of CompuGroup Medical SE & Co. KGaA ("CGM"), as a part of our portfolio management strategy. Such operations included the associates, intellectual property, client contracts, other assets, and liabilities related to our medico®, Selene®, Soarian Health Archive®, and Soarian® Integrated Care solution offerings. | ||||
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | R1 RCM Inc. [Member] | |||||
Discontinued Operations and Disposal Groups [Abstract] | |||||
Disposal Group, Including Discontinued Operation, Description and Timing of Disposal | On August 3, 2020, we sold certain of our revenue cycle outsourcing business operations to affiliates of R1 RCM Inc., as a part of our portfolio management strategy. Such operations included the associates, client contracts, certain other assets, and certain liabilities related to our commercial revenue cycle outsourcing services business. | ||||
Gain on sale of businesses | $ 2,000 | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Disposal Group, Including Discontinued Operation, Description and Timing of Disposal | On August 3, 2020, we sold certain of our revenue cycle outsourcing business operations to affiliates of R1 RCM Inc., as a part of our portfolio management strategy. Such operations included the associates, client contracts, certain other assets, and certain liabilities related to our commercial revenue cycle outsourcing services business. |
Income Taxes (Details)
Income Taxes (Details) | 9 Months Ended | |
Sep. 30, 2020 | Sep. 28, 2019 | |
Income Tax Disclosure [Abstract] | ||
Effective tax rate | 21.70% | 18.90% |
Earnings Per Share (Reconciliat
Earnings Per Share (Reconciliation Of The Numerators And The Denominators Of The Basic And Diluted Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 28, 2019 | Sep. 30, 2020 | Sep. 28, 2019 | |
Earnings Per Share [Abstract] | ||||
Income available to common shareholders, basic | $ 356,676 | $ 81,935 | $ 638,583 | $ 375,123 |
Income available to common shareholders including assumed conversions, diluted | $ 356,676 | $ 81,935 | $ 638,583 | $ 375,123 |
Basic weighted average shares outstanding | 305,759 | 315,876 | 306,759 | 320,282 |
Stock options and non-vested shares, incremental shares | 2,607 | 3,237 | 2,365 | 3,079 |
Diluted weighted average shares outstanding | 308,366 | 319,113 | 309,124 | 323,361 |
Basic earnings per share | $ 1.17 | $ 0.26 | $ 2.08 | $ 1.17 |
Diluted earnings per share | $ 1.16 | $ 0.26 | $ 2.07 | $ 1.16 |
Earnings Per Share (Narrative)
Earnings Per Share (Narrative) (Details) - $ / shares shares in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 28, 2019 | Sep. 30, 2020 | Sep. 28, 2019 | |
Earnings Per Share [Abstract] | ||||
Antidilutive securities excluded from computation of earnings per share, amount | 3.9 | 7.7 | 4.4 | 10.1 |
Antidilutive securities excluded from computation of earnings per share, exercise price, lower range limit | $ 55.24 | $ 54.87 | $ 52.32 | $ 51.87 |
Antidilutive securities excluded from computation of earnings per share, exercise price, upper range limit | $ 76.49 | $ 75.83 | $ 76.49 | $ 75.83 |
Share-Based Compensation (Sched
Share-Based Compensation (Schedule Of Stock Options Activity) (Details) $ / shares in Units, shares in Thousands, $ in Thousands | 9 Months Ended |
Sep. 30, 2020USD ($)$ / sharesshares | |
Share-based Payment Arrangement [Abstract] | |
Outstanding at beginning of year, number of shares | shares | 15,416 |
Outstanding at beginning of year, weighted-average exercise price | $ / shares | $ 56.36 |
Granted, number of shares | shares | 3 |
Granted, weighted-average exercise price | $ / shares | $ 72.36 |
Exercised, number of shares | shares | (4,009) |
Exercised, weighted-average exercise price | $ / shares | $ 50.67 |
Forfeited and expired, number of shares | shares | (228) |
Forfeited and expired, weighted-average exercise price | $ / shares | $ 61.32 |
Outstanding end of year, number of shares | shares | 11,182 |
Outstanding at end of year, weighted-average exercise price | $ / shares | $ 58.31 |
Outstanding at end of year, aggregate intrinsic value | $ | $ 156,372 |
Outstanding at end of year, weighted-average remaining contractual term | 5 years 8 months 12 days |
Exercisable at end of year, number of shares | shares | 7,248 |
Exercisable at end of year, weighted-average exercise price | $ / shares | $ 56.87 |
Exercisable at end of year, aggregate intrinsic value | $ | $ 111,738 |
Exercisable at end of year, weighted-average remaining contractual term | 4 years 10 months 6 days |
Share-Based Compensation (Sch_2
Share-Based Compensation (Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions) (Details) | 9 Months Ended |
Sep. 30, 2020$ / shares | |
Share-based Payment Arrangement [Abstract] | |
Expected volatility (%) | 24.50% |
Expected dividend rate | 1.00% |
Expected term (yrs) | 6 years |
Risk-free rate (%) | 1.10% |
Fair value per option | $ 16.64 |
Share-Based Compensation (Sch_3
Share-Based Compensation (Schedule Of Non-Vested Shares Activity) (Details) - Restricted Stock [Member] shares in Thousands | 9 Months Ended |
Sep. 30, 2020$ / sharesshares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Outstanding at beginning of year, number of shares | shares | 2,634 |
Outstanding at beginning of year, weighted-average grant date fair value | $ / shares | $ 65.30 |
Granted, number of shares | shares | 2,520 |
Granted, weighted-average grant date fair value | $ / shares | $ 69.99 |
Vested, number of shares | shares | (946) |
Vested, weighted-average grant date fair value | $ / shares | $ 66.30 |
Forfeited, number of shares | shares | (97) |
Forfeited, weighted-average grant date fair value | $ / shares | $ 67.24 |
Outstanding at end of year, number of shares | shares | 4,111 |
Outstanding at end of year, weighted-average grant date fair value | $ / shares | $ 67.90 |
Share-Based Compensation (Compe
Share-Based Compensation (Compensation Expense Recognized In The Condensed Consolidated Statements Of Operations) (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 28, 2019 | Sep. 30, 2020 | Sep. 28, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Amounts charged against earnings, before income tax benefit | $ 38,137 | $ 31,782 | $ 111,724 | $ 78,103 |
Amount of related income tax benefit recognized in earnings | 7,818 | 6,330 | 22,452 | 14,888 |
Stock option and non-vested share compensation expense | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Amounts charged against earnings, before income tax benefit | 37,920 | 30,537 | 110,500 | 73,421 |
Associate stock purchase plan expense | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Amounts charged against earnings, before income tax benefit | 1,367 | 1,321 | 4,195 | 4,612 |
Amounts capitalized in software development costs, net of amortization | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Amounts charged against earnings, before income tax benefit | $ (1,150) | $ (76) | $ (2,971) | $ 70 |
Schedule of Accumulated Other C
Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands | 3 Months Ended | |||||||
Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Sep. 28, 2019 | Jun. 29, 2019 | Mar. 30, 2019 | Dec. 28, 2019 | Dec. 29, 2018 | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Accumulated other comprehensive loss, net | $ (138,015) | $ (149,671) | $ (159,363) | $ (128,550) | $ (112,848) | $ (100,594) | $ (118,660) | $ (103,552) |
OCI, before Reclassifications, Net of Tax, Attributable to Parent | 9,102 | 7,494 | (41,825) | (15,797) | (12,107) | 2,958 | ||
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent | 2,554 | 2,198 | 1,122 | 95 | (147) | 0 | ||
Accumulated Foreign Currency Adjustment Attributable to Parent | ||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Accumulated other comprehensive loss, net | (108,085) | (117,696) | (126,893) | (112,397) | (100,718) | (100,618) | (106,347) | (102,939) |
OCI, before Reclassifications, Net of Tax, Attributable to Parent | 9,611 | 9,197 | (20,546) | (11,679) | (100) | 2,321 | ||
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent | 0 | 0 | 0 | 0 | 0 | 0 | ||
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent | ||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Accumulated other comprehensive loss, net | (30,628) | (32,893) | (31,886) | (16,407) | (12,370) | 0 | (12,578) | 0 |
OCI, before Reclassifications, Net of Tax, Attributable to Parent | (289) | (3,205) | (20,430) | (4,135) | (12,223) | 0 | ||
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent | 2,554 | 2,198 | 1,122 | 98 | (147) | 0 | ||
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent | ||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Accumulated other comprehensive loss, net | 698 | 918 | (584) | 254 | 240 | 24 | $ 265 | $ (613) |
OCI, before Reclassifications, Net of Tax, Attributable to Parent | (220) | 1,502 | (849) | 17 | 216 | 637 | ||
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent | $ 0 | $ 0 | $ 0 | $ (3) | $ 0 | $ 0 |
Reclassification out of Accumul
Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 28, 2019 | Sep. 30, 2020 | Sep. 28, 2019 | |
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Other income, net | $ 48,020 | $ 13,535 | $ 78,247 | $ 44,973 |
Income Tax Expense (Benefit) | (103,164) | (20,377) | (176,758) | (87,688) |
Net earnings | 356,676 | 81,935 | 638,583 | 375,123 |
Reclassification out of Accumulated Other Comprehensive Income | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Net earnings | (2,554) | (95) | (5,874) | 52 |
Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Other income, net | (3,213) | (122) | (7,383) | 58 |
Income Tax Expense (Benefit) | 659 | 24 | 1,509 | (9) |
Net earnings | (2,554) | (98) | (5,874) | 49 |
Reclassification out of Accumulated Other Comprehensive Income | AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Other income, net | 0 | 4 | 0 | 4 |
Income Tax Expense (Benefit) | 0 | 1 | 0 | 1 |
Net earnings | $ 0 | $ 3 | $ 0 | $ 3 |
Share-Based Compensation (Narra
Share-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Sep. 30, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Share-based Awards Other than Options | $ 223 | $ 223 | ||
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options | 58 | 58 | ||
Stock Repurchase Program, Authorized Amount | 3,700 | 3,700 | ||
Stock Repurchase Program, Remaining Authorized Repurchase Amount | $ 1,030 | $ 1,030 | ||
Dividends Payable, Date Declared | Sep. 10, 2020 | May 21, 2020 | Mar. 19, 2020 | |
Dividends Payable, Amount Per Share | $ 0.18 | $ 0.18 | $ 0.18 | $ 0.18 |
Dividends Payable, Date to be Paid | Oct. 13, 2020 | Jul. 17, 2020 | Apr. 17, 2020 | |
Dividends Payable, Date of Record | Sep. 25, 2020 | Jun. 5, 2020 | Apr. 3, 2020 | |
Dividends Payable | $ 56 | $ 56 | ||
Treasury stock purchases | $ 650 | |||
Treasury Stock, Shares, Acquired | 9,200 | |||
Stock Options [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Period of recognition for remaining share-based compensation expense | 2 years 1 month 13 days | |||
Restricted Stock [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Period of recognition for remaining share-based compensation expense | 1 year 11 months 15 days |
Contingencies Contingencies (De
Contingencies Contingencies (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended |
Dec. 29, 2018 | Sep. 30, 2020 | |
Fujitsu [Member] | ||
Commitments and Contingencies Disclosure [Abstract] | ||
Loss Contingency, Management's Assessment and Process | As previously disclosed, we continue to be in dispute with Fujitsu Services Limited ("Fujitsu") regarding Fujitsu's obligation to pay amounts to us due upon the termination of a subcontract, including client receivables, in connection with Fujitsu's contract as the prime contractor in the National Health Service ("NHS") initiative to automate clinical processes and digitize medical records in the Southern region of England. The NHS terminated its contract with Fujitsu, which gave rise to the termination of our subcontract with Fujitsu. We filed a request for arbitration with the London Court of International Arbitration on April 22, 2019 seeking damages. On December 30, 2019, Fujitsu filed its Defense and Counterclaim (the "Counterclaim") in response. In its Counterclaim, Fujitsu defends against our claim in full and argues that we are liable to Fujitsu for: (i) £306 million in damages based on our alleged fraudulent misrepresentations inducing Fujitsu to enter into the subcontract; or (ii) alternatively, £173.8 million in damages based on our alleged breaches of the subcontract. | |
Loss Contingencies [Line Items] | ||
Loss Contingency, Management's Assessment and Process | As previously disclosed, we continue to be in dispute with Fujitsu Services Limited ("Fujitsu") regarding Fujitsu's obligation to pay amounts to us due upon the termination of a subcontract, including client receivables, in connection with Fujitsu's contract as the prime contractor in the National Health Service ("NHS") initiative to automate clinical processes and digitize medical records in the Southern region of England. The NHS terminated its contract with Fujitsu, which gave rise to the termination of our subcontract with Fujitsu. We filed a request for arbitration with the London Court of International Arbitration on April 22, 2019 seeking damages. On December 30, 2019, Fujitsu filed its Defense and Counterclaim (the "Counterclaim") in response. In its Counterclaim, Fujitsu defends against our claim in full and argues that we are liable to Fujitsu for: (i) £306 million in damages based on our alleged fraudulent misrepresentations inducing Fujitsu to enter into the subcontract; or (ii) alternatively, £173.8 million in damages based on our alleged breaches of the subcontract. | |
Loss Contingency Accrual, Provision | $ 45 | |
NextGen [Member] | ||
Commitments and Contingencies Disclosure [Abstract] | ||
Loss Contingency, Management's Assessment and Process | Cerner Health Services, Inc. ("Cerner HS"), a wholly owned subsidiary of Cerner Corporation, filed a lawsuit in the Chester County, Pennsylvania, Court of Common Pleas against NextGen Healthcare Information Systems, LLC ("NextGen") relating to a dispute arising out of a supplier relationship initially established between Siemens Health Services, Inc. ("Health Services") and NextGen prior to the acquisition of the assets of Health Services by Cerner HS in 2015. In September 2017, the court issued a preliminary injunction to prevent NextGen from refusing to honor certain contractual obligations to support Cerner HS's clients who use NextGen ambulatory EHR solutions. In September 2018, NextGen filed a counterclaim alleging breach of contract and tortious interference but did not specify its damages. In August 2019, NextGen provided an expert report alleging profit disgorgement damages of $135 million or, alternatively, $30.5 million in lost profit damages, but the report did not discuss how our actions allegedly caused NextGen's damages. In December 2019, we deposed NextGen's expert, gaining additional clarity on categories of alleged damages but not on the alleged theories of liability. A jury trial is set to begin on January 25, 2021. We believe NextGen's claims are without merit and will vigorously defend against them; however, there can be no assurances as to the outcome of the dispute. We have not concluded that a loss related to the claims raised by NextGen in its counterclaim is probable, nor have we accrued a liability related to these claims. Although a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss in light of the inherent difficulty of predicting the outcome of litigation generally, the wide range of damages presented by NextGen's expert, and the continued lack of clarity on the causal connection between Cerner Corporation's and Cerner HS's actions and any alleged damages. | |
Loss Contingencies [Line Items] | ||
Loss Contingency, Management's Assessment and Process | Cerner Health Services, Inc. ("Cerner HS"), a wholly owned subsidiary of Cerner Corporation, filed a lawsuit in the Chester County, Pennsylvania, Court of Common Pleas against NextGen Healthcare Information Systems, LLC ("NextGen") relating to a dispute arising out of a supplier relationship initially established between Siemens Health Services, Inc. ("Health Services") and NextGen prior to the acquisition of the assets of Health Services by Cerner HS in 2015. In September 2017, the court issued a preliminary injunction to prevent NextGen from refusing to honor certain contractual obligations to support Cerner HS's clients who use NextGen ambulatory EHR solutions. In September 2018, NextGen filed a counterclaim alleging breach of contract and tortious interference but did not specify its damages. In August 2019, NextGen provided an expert report alleging profit disgorgement damages of $135 million or, alternatively, $30.5 million in lost profit damages, but the report did not discuss how our actions allegedly caused NextGen's damages. In December 2019, we deposed NextGen's expert, gaining additional clarity on categories of alleged damages but not on the alleged theories of liability. A jury trial is set to begin on January 25, 2021. We believe NextGen's claims are without merit and will vigorously defend against them; however, there can be no assurances as to the outcome of the dispute. We have not concluded that a loss related to the claims raised by NextGen in its counterclaim is probable, nor have we accrued a liability related to these claims. Although a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss in light of the inherent difficulty of predicting the outcome of litigation generally, the wide range of damages presented by NextGen's expert, and the continued lack of clarity on the causal connection between Cerner Corporation's and Cerner HS's actions and any alleged damages. |
Segment Reporting (Summary Of T
Segment Reporting (Summary Of The Operating Information) (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 28, 2019 | Sep. 30, 2020 | Sep. 28, 2019 | |
Segment Reporting Information [Line Items] | ||||
Revenues | $ 1,368,673 | $ 1,429,428 | $ 4,110,763 | $ 4,250,366 |
Costs of revenue | 231,889 | 271,778 | 698,268 | 793,655 |
Operating expenses | 941,833 | 1,068,873 | 2,892,270 | 3,038,873 |
Total costs and expenses | 1,173,722 | 1,340,651 | 3,590,538 | 3,832,528 |
Gain on sale of businesses | 216,869 | 0 | 216,869 | 0 |
Operating earnings (loss) | 411,820 | 88,777 | 737,094 | 417,838 |
Domestic Segment | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | 1,230,769 | 1,265,263 | 3,645,397 | 3,762,205 |
Costs of revenue | 219,938 | 246,634 | 638,284 | 719,119 |
Operating expenses | 566,777 | 639,590 | 1,724,545 | 1,817,244 |
Total costs and expenses | 786,715 | 886,224 | 2,362,829 | 2,536,363 |
Gain on sale of businesses | 0 | 0 | ||
Operating earnings (loss) | 444,054 | 379,039 | 1,282,568 | 1,225,842 |
International Segment [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | 137,904 | 164,165 | 465,366 | 488,161 |
Costs of revenue | 11,951 | 25,144 | 59,984 | 74,536 |
Operating expenses | 58,626 | 68,153 | 182,594 | 209,580 |
Total costs and expenses | 70,577 | 93,297 | 242,578 | 284,116 |
Gain on sale of businesses | 0 | 0 | ||
Operating earnings (loss) | 67,327 | 70,868 | 222,788 | 204,045 |
Other | ||||
Segment Reporting Information [Line Items] | ||||
Operating expenses | 316,430 | 361,130 | 985,131 | 1,012,049 |
Total costs and expenses | 316,430 | 361,130 | 985,131 | 1,012,049 |
Gain on sale of businesses | 216,869 | 216,869 | ||
Operating earnings (loss) | $ (99,561) | $ (361,130) | $ (768,262) | $ (1,012,049) |